Document:

EX-10.1

EXHIBIT 10.1

ENDOCYTE, INC.

2010 EQUITY INCENTIVE PLAN

PERFORMANCE-BASED RESTRICTED STOCK UNIT

AWARD AGREEMENT

(2011 RSU PROGRAM)

This Award Agreement (“Award Agreement”), dated as of May 26, 2011, is by and between
Endocyte, Inc., a Delaware corporation (the “Company”), and        (“Participant”). Unless
otherwise defined herein, the terms defined in the Endocyte, Inc. 2010 Equity Incentive Plan (the
“Plan”), shall have the same defined meanings in this Award Agreement.

	I.	 	NOTICE OF GRANT

	 	 	 	Participant:

The Company has granted the Participant an award of performance-based restricted stock units
(“RSUs”), subject to the terms and conditions of the Plan and this Award Agreement, as follows:

	 	 	 
	Target Number of RSUs:
	 	

	Maximum Number of RSUs:
	 	

	Award Date:
	 	May 26, 2011

	Performance Measure:
	 	The Performance Measure shall be the approval, with

respect to any country or jurisdiction, of the

applicable Regulatory Authority to manufacture and

sell a product in that country or jurisdiction (the

“Commercial Approval”).

“Regulatory Authority” means, with respect to any

country or jurisdiction, the governmental agency or

authority that regulates the testing, investigation,

manufacture, marketing and sale of human

pharmaceutical products, including without limitation

the Food and Drug Administration in the United States

and the European Medicines Agency in the European

Union.

	Performance Deadline:
	 	May 26, 2016

II. AGREEMENT

1. Grant of Award. As of the Award Date indicated in the Notice of Grant above, the
Company hereby grants to Participant an award of RSUs (the “Award”), subject to the terms and
conditions of the Plan, which is incorporated herein by reference, and this Award Agreement. Until
the RSUs are actually settled and paid, each RSU represents an unfunded and unsecured obligation of
the Company of an amount equal to the Fair Market Value of one Share, subject to certain
performance-based and service-based vesting requirements and the other restrictions, terms and
conditions contained in this Award Agreement and the Plan. Except as may be required by law,
Participant is not required to make any payment (other than payments for taxes pursuant to the
Plan) or provide any consideration other than the rendering of future services to the Company.

2. General.

(a) No RSUs shall be earned unless and until the Compensation Committee of the Board of
Directors of the Company (the “Committee”) shall have determined whether First Commercial Approval
(as defined in paragraph 3(b) below) or Second Commercial Approval (as defined in paragraph 3(b)
below) have been obtained by the Performance Deadline.

(b) This Award does not entitle Participant to any rights of a holder of Common Stock,
including dividends or voting rights. Participant shall have no rights as a stockholder with
respect to any Shares issuable in respect of such RSUs, until the RSUs are actually settled and
paid in the form of Shares delivered to and held of record by Participant.

3. Vesting. Unless otherwise provided in this Award Agreement or in the Plan, the RSUs
shall be subject to the following conditions for vesting:

(a) The Committee shall determine whether First Commercial Approval or Second Commercial
Approval has been obtained and the number, if any, of RSUs earned. The date on which the Committee
makes its determination as to First Commercial Approval is hereinafter referred to as the “First
Determination Date”. The date on which the Committee makes its determination as to Second
Commercial Approval is hereinafter referred to as the “Second Determination Date”.

(b) The target number of RSUs as set forth above will be earned (the “Target Earned RSUs”)
upon receipt of the first Commercial Approval from any Regulatory Authority for any therapeutic
compound or product of the Company (the “First Commercial Approval”), provided that such approval
is granted on or before the Performance Deadline. The difference between the maximum number of RSUs
and target number of RSUs will be earned (the “Incremental Earned RSUs”, and together with the
Target Earned RSUs, the “Earned RSUs”) upon receipt of the second Commercial Approval from any
Regulatory Authority (which may, but need not, be the same Regulatory Authority that granted the
First Commercial Approval) for any therapeutic compound or product of the Company (the “Second
Commercial Approval”), provided that such approval is granted on or before the Performance
Deadline.

(c) Except as otherwise set forth in this Award Agreement, one-half of the Target Earned RSUs
shall become vested and nonforfeitable on the First Determination Date, provided Participant has
maintained its relationship as a Service Provider. The second half of the Target Earned RSUs shall
become vested and nonforfeitable on the first anniversary of the First Determination Date, provided
Participant has maintained its relationship as a Service Provider. Except as otherwise set forth
in this Award Agreement, one-half of the Incremental Earned RSUs shall become vested and
nonforfeitable on the Second Determination Date, provided Participant has maintained its
relationship as a Service Provider. The second half of the Incremental Earned RSUs shall become
vested and nonforfeitable on the first anniversary of the Second Determination Date, provided
Participant has maintained its relationship as a Service Provider.

4. Restrictions and Forfeitures. If First Commercial Approval is not obtained by the
Performance Deadline, all RSUs in this Award shall be cancelled and forfeited to the Company. If
Second Commercial Approval is not obtained by the Performance Deadline, the difference between the
maximum number of RSUs and target number of RSUs in this Award shall be cancelled and forfeited to
the Company. If Participant ceases to be a Service Provider for any reason, all RSUs that are not
fully vested and nonforfeitable shall be immediately cancelled and forfeited to the Company.

5. Change in Control. Upon the occurrence of a Change in Control, the unvested RSUs
will be considered fully vested and earned immediately prior to consummation such Change in
Control.

6. Payment. Except as provided otherwise in this Award Agreement, Earned RSUs will be
settled and paid as soon as practicable after the date on which they become vested and
nonforfeitable, but in no event later than the 15th day of the third month following
such date. Payment may be made in cash, in Shares (in the amount of one Share for each Earned
RSU), or a combination of both, as determined by the Company in its discretion.

7. Non-Transferability of RSUs. Neither the RSUs nor any interest therein may be
sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by
will or by the laws of descent or distribution. Any purported sale, pledge, assignment,
hypothecation, transfer or other disposition in violation of this Award Agreement or the Plan will
be void and of no effect. The terms of the Plan and this Award Agreement shall be binding upon the
executors, administrators, heirs, successors and assigns of Participant.

8. Taxes. Participant may satisfy Participant’s tax withholding obligation, in whole
or in part by (a) paying cash, (b) electing to have the Company withhold otherwise deliverable
Shares having a Fair Market Value equal to the minimum statutory amount required to be withheld, or
(c) delivering to the Company already-owned Shares having a Fair Market Value equal to the minimum
statutory amount required to be withheld. The Fair Market Value of the Shares to be withheld or
delivered will be determined as of the date that the taxes are required to be withheld.

1

	III.	 	OTHER TERMS

9. Entire Agreement; Governing Law. The Plan is incorporated herein by reference. The
Plan and this Award Agreement constitute the entire agreement of the parties with respect to the
subject matter hereof and supersede in their entirety all prior undertakings and agreements of the
Company and Participant with respect to the subject matter hereof, and may not be modified
adversely to Participant’s interest except by means of a writing signed by the Company and
Participant. This Award Agreement is governed by the internal substantive laws but not the choice
of law rules of Indiana.

10. Notices. All notices and other communications required or permitted under this
Award Agreement shall be written and delivered personally or sent by registered or certified
first-class mail, postage prepaid and return receipt required, addressed as follows: if to the
Company, to the Company’s executive offices in West Lafayette, Indiana, and if to Participant or
his or her successor, to the residence address last furnished by Participant to the Company.
Notwithstanding the foregoing, the Company may authorize notice by any other means it deems
desirable or efficient at a given time, such as notice by facsimile or electronic mail (e-mail).
Participant agrees to notify the Company upon any change in Participant’s residence address.

11. No Guarantee of Continued Service. PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE
AWARD WILL BE EARNED ONLY BY ACHIEVING THE PERFORMANCE MEASURE AND CONTINUING AS A SERVICE PROVIDER
AT THE WILL OF THE COMPANY (NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS AWARD OR
ACQUIRING SHARES HEREUNDER). PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES THAT THIS AWARD AGREEMENT
AND THE TRANSACTIONS CONTEMPLATED HEREUNDER DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF
CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE PERFORMANCE PERIOD, FOR ANY PERIOD, OR AT ALL,
AND SHALL NOT INTERFERE IN ANY WAY WITH PARTICIPANT’S RIGHT OR THE COMPANY’S RIGHT TO TERMINATE THE
PARTICIPANT’S RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR WITHOUT CAUSE.

12. Plan Controlling. Subject to Section 18(c) of the Plan, in the event of a
conflict between the terms and conditions of the Plan and this Award Agreement, the terms and
conditions of the Plan shall prevail. Participant acknowledges receipt of a copy of the Plan and
represents that he or she is familiar with the terms and provisions thereof, and hereby accepts
this Award subject to all of the terms and provisions thereof. Participant has reviewed the Plan
and this Award Agreement in their entirety, has had an opportunity to obtain the advice of counsel
prior to executing this Award Agreement and fully understands all provisions of the Award
Agreement. Participant hereby agrees to accept as binding, conclusive and final all decisions or
interpretations of the Administrator upon any questions arising under the Plan or this Award
Agreement.

The Company and Participant have executed this Award Agreement as of the date first written
above.

	 	 	 	 	 	 	 	 	 
	PARTICIPANT	 	 	 	ENDOCYTE, INC.
	 	 
	                        
	 	 	 	 By:

	 	                           
	 	

	 
	 	 	 	
 
	 	 
	 	

	 	 	        	 	Name:
	 	                
	 	 	 	 	Title:
	 	 

2EX-10.1

INVESTMENT AGREEMENT

DATED AS OF

MAY 26, 2011

BETWEEN

FIRST BANCORP

AND

THE INVESTORS NAMED ON THE SIGNATURE PAGES HERETO

TABLE OF CONTENTS

PAGE

	 	 	 	 	 
	ARTICLE 1 PURCHASE OF SHARES
	 	1.1	 	 	Purchase of Shares.

	 	 	 
	ARTICLE 2 THE CLOSING TRANSACTIONS
	2.1

2.2
	 	Closing.

Actions on the Closing Date.

	 	 	 
	ARTICLE 3 REPRESENTATIONS AND WARRANTIES
	3.1

3.2
	 	Representations and Warranties of the Company.

Representations and Warranties of the Investors.

	 	 	 
	ARTICLE 4 ACTIONS PRIOR TO THE TRANSACTION
	4.1

4.2

4.3

4.4

4.5

4.6

4.7

4.8

4.9

4.10
	 	Stockholder Approval.

HSR Act Filings.

Listing of Shares.

Change of Bank Control Act and Bank Holding Company Act.

Most Favored Terms.

Notice of Adverse Occurrences.

Reasonable Best Efforts.

Election of Independent Chairman; Board Representative.

Access; Confidentiality

Conduct of the Business

	 	 	 
	ARTICLE 5 CONDITIONS PRECEDENT TO TRANSACTION
	5.1

5.2

5.3
	 	Conditions to the Company’s Obligations.

Conditions to the Investor’s Obligations.

Waiver of Conditions to Investor’s Obligations.

	 	 	 
	ARTICLE 6 ADDITIONAL AGREEMENTS
	6.1

6.2

6.3

6.4

6.5
	 	Company Obligation Regarding Adequate Public Information.

Efforts to Maintain Listing.

Additional Regulatory Matters

Percentage Maintenance Rights

Participation in Other Offerings.

	 	 	 	 	 
	ARTICLE 7 SALE RESTRICTIONS
	 	7.1	 	 	Restrictions on Sales of Acquired Common Stock.

	 	 	 
	ARTICLE 8 SECURITIES ACT REGISTRATION
	8.1

8.2

8.3

8.4

8.5

8.6
	 	Obligation to Register Acquired Common Stock.

Obligations of the Investors Regarding Registration.

Indemnification Regarding Disclosures.

Assignment of Registration Rights.

Lock Up Agreements.

Holdback.

	 	 	 
	ARTICLE 9 TERMINATION
	9.1

9.2

9.3
	 	Right to Terminate.

Manner of Terminating Agreement.

Effect of Termination.

	 	 	ARTICLE 10 INDEMNIFICATION	 

	 	10.1	 	Indemnification Against Loss Due to Inaccuracies in Company’s
Representations and Warranties or Company Failure to Fulfill Obligations.	 

	 	10.2	 	Indemnification Against Loss Due to Inaccuracies in Investor’s
Representations and Warranties or Investor Failure to Fulfill Obligations.	 

	 	10.3	 	Limit on Liability for Breach of Warranty.	 

	 	10.4	 	Indemnification Sole Remedy.	 

	 	 	 
	ARTICLE 11 ABSENCE OF BROKERS
	11.1

11.2
	 	Representations and Warranties Regarding Brokers and Others.

Expenses.

	 	 	 
	ARTICLE 12 GENERAL
	12.1

12.2

12.3

12.4

12.5

12.6

12.7

12.8

12.9

12.10

12.11

12.12

12.13

12.14

12.15

12.16
	 	Announcement of Transaction.

Entire Agreement.

Benefit of Agreement.

Captions.

Assignments.

Notices and Other Communications.

Governing Law.

Consent to Jurisdiction.

Remedies; Specific Performance.

Non-Recourse.

Waiver of Jury Trial.

Amendments.

Interpretation.

Mutual Drafting.

Severability.

Counterparts.

LIST OF EXHIBITS

	 	 	 
	Exhibit A

Exhibit B

Exhibit C

	 	Illustrative Pro Forma Capitalization of the Company

Form of Opinion of K&L Gates LLP

Form of Opinion of Martinez Odell & Calabria

INVESTMENT AGREEMENT

This agreement (the “Agreement”) is dated as of May 26, 2011 among First BanCorp (the
“Company”), a Puerto Rico chartered financial holding company, and each of the investors that have
signed this Agreement (each an “Investor” and together, the “Investors”), relating to the sale by
the Company to each of the Investors of the number of shares of common stock of the Company
(“Common Stock”), par value $0.10 per share, shown opposite the name of each such Investor on the
signature pages of this Agreement. Now, therefore, in consideration of the premises, and of the
representations, warranties, covenants and agreements set forth herein, and intending to be legally
bound, the parties hereby agree as follows:

ARTICLE 1

PURCHASE OF SHARES

1.1 Purchase of Shares. Subject to the conditions contained in this Agreement, on
the Closing Date described in Section 2.1, each Investor will purchase from the Company,
and the Company will sell to each Investor, the lesser of (x) 24.9% of all the shares of Common
Stock that will be outstanding after the issuances of Common Stock to all Other Investors on the
Closing Date, and the conversion of the Company’s the Company’s fixed rate cumulative mandatorily
convertible preferred stock, Series G (“Series G Preferred Stock into Common Stock, or (y) the
maximum amount that will not result in such Investor or any of its affiliates being in control of
the Company or of FirstBank for purposes of the Bank Holding Company Act or the Federal Reserve
Board’s Regulation Y, or otherwise being subject to regulation as a bank holding company under that
Act (the shares being purchased by all the Investors being the “Acquired Common Stock”) for the
purchase price of the lesser of (a) $3.50 per share of Common Stock or (b) such price as may be
agreed with any Other Investor (the “Per Share Price”). Exhibit A contains hypothetical examples
illustrating how the number of shares of Acquired Common Stock would be calculated if the Investors
and Other Investors purchase Common Stock for (i) $500 million and (ii) $515 million (equal to $550
million minus the $35 million purchase price of the shares that would be issuable on exercise of
rights expected to be issued to holders of Common Stock that is outstanding prior to the Closing
Date (the “Rights Offering”), respectively, and in either event, all the Company’s fixed rate
cumulative mandatorily convertible preferred stock, Series G (“Series G Preferred Stock”) is
converted into Common Stock. The Per Share Price shall be adjusted to reflect appropriately the
effect of any stock split, reverse stock split, stock dividend (including any dividend or
distribution of securities convertible into Common Stock), extraordinary cash dividends,
reorganization, recapitalization, reclassification, combination, exchange of shares or other like
change with respect to Common Stock (other than the conversion of the Series G Preferred Stock into
Common Stock) occurring on or after the date hereof and prior to the Closing.

ARTICLE 2

THE CLOSING TRANSACTIONS

2.1 Closing. Subject to the satisfaction or waiver of the conditions set forth in
this Agreement, the closing of the sale of Common Stock described in Article 1 will take
place at the offices of K&L Gates, LLP, 599 Lexington Avenue, New York, NY 10019, or by electronic
exchange of documents and signature pages, on the day (the “Closing Date”) that is the second
Business Day after the day on which all the conditions in Article 5 (other than conditions
that by their terms cannot be fulfilled until the Closing Date, but subject to the satisfaction or
waiver of such conditions) are satisfied, or at such other place and time as is agreed upon by the
parties. As used in this Agreement, the term “Business Day” means a day that is not a Saturday, a
Sunday or a day on which banks in New York City or in San Juan, Puerto Rico generally are required
or permitted not to be open for banking business.

2.2 Actions on the Closing Date. Not later than 11:00 a.m., New York City time, on
the Closing Date, each Investor will transmit to an account of the Company with a bank in New York
City that is specified by the Company at least two Business Days before the Closing Date
immediately available funds equal to the full amount of the purchase price for the Acquired Common
Stock to be purchased by such Investor in accordance with Section 1.1 (the “Aggregate
Purchase Price””). Upon receipt by the Company of confirmation that such funds have been received,
the Company will instruct The Bank of New York Mellon Shareholder Services (or its successor), as
transfer agent, to issue the Acquired Common Stock to the Investor in book entry form. The
depositary that holds the Acquired Common Stock may be instructed to note on its records that the
Acquired Common Stock (a) has been issued without registration under the Securities Act of 1933, as
amended (the “Securities Act”), and may not be sold or transferred other than in a transaction that
is registered under the Securities Act or is exempt from the registration requirements of the
Securities Act (which notation will be withdrawn when resale of the Acquired Common Stock has been
registered under the Securities Act as contemplated by Article 8), and (b) is subject to
the sale restrictions contained in Article 7. On the Closing Date, the Company shall also
deliver or cause to be delivered to each Investor (x) a receipt for the Aggregate Purchase Price
paid by that Investor; and (y) a true and complete copy, certified by the Secretary or an Assistant
Secretary of the Company, of the resolutions duly and validly adopted by the Board of Directors of
the Company evidencing its authorization of the execution and delivery of this Agreement and the
consummation of the transactions contemplated hereby.

ARTICLE 3

REPRESENTATIONS AND WARRANTIES

3.1 Representations and Warranties of the Company. The Company represents and
warrants to the Investors as follows:

(a) Organization and Power. The Company is a corporation duly organized, validly
existing and in good standing under the laws of the Commonwealth of Puerto Rico. The Company is
duly registered as a financial holding company under the U.S. Bank Holding Company Act of 1956, as
amended (the “Bank Holding Company Act”). Each of the Company and each Company Subsidiary,
including each Company Subsidiary that is a Significant Subsidiary (as that term is defined in Rule
1.02 of Securities and Exchange Commission (“SEC”) Regulation S-X), including FirstBank Puerto Rico
(“FirstBank”), has all the corporate power and authority that is required to enable it to conduct
its business as it is being conducted at the date of this Agreement. The Company and each Company
Subsidiary is duly qualified to do business and is in good standing in every jurisdiction in which
qualification is required, except jurisdictions in which failure to qualify would not have a
Company Material Adverse Effect. The Company has furnished to the Investors or has filed via
“Edgar” with the SEC true, correct and complete copies of the Company’s Articles of Incorporation
and By-Laws, as amended through the date of this Agreement. For purposes of this Agreement,
“Previously Disclosed” means (i) information publicly disclosed by the Company in the Company
Reports filed by it with or furnished to the SEC and publicly available via the Edgar system prior
to the date of this Agreement (excluding any risk factor disclosures contained in such documents
and any disclosure of risks included in any forward-looking statements disclaimer or other
statements that are similarly non-specific or are predictive or forward-looking in nature), or (ii)
documents made available to the Investors prior to the date of this Agreement either physically or
in an electronic data room to which the Investors or their representatives had access and the
information contained in those documents, in each of (i) and (ii), prior to and until 11:59 p.m. on
May 23, 2011, or (iii) information about tax audits and the extension of the period of limitations
with respect to a U.S. Internal Revenue Service tax audit made available to the Investors prior to
and until 11:59 p.m. on May 25,2011).

(b) “Company Material Adverse Effect.” As used in this Agreement, the term “Company
Material Adverse Effect” means any circumstance, change, effect, event or fact the effect of which,
individually or in the aggregate, (i) is, or would reasonably be expected to be, materially adverse
to the business, assets, liabilities, results of operations or financial condition of the Company
and its consolidated Company Subsidiaries taken as a whole or (ii) prevents or materially delays or
materially impairs the ability of the Company to perform its obligations under this Agreement and
to consummate the transactions contemplated hereby; provided, however, that the
term Company Material Adverse Effect will not include any circumstance, change, effect, event or
fact arising from (A) changes after the date of this Agreement in general business, economic or
market conditions in the United States or the Commonwealth of Puerto Rico (including changes
generally in prevailing interest rates, credit availability and liquidity, currency exchange rates
and price levels or trading volumes in the United States or foreign securities or credit markets),
or any outbreak or escalation of hostilities, declared or undeclared acts of war or terrorism, in
each case generally affecting the industries in which the Company and the Company Subsidiaries
operate, (B) changes or proposed changes after the date of this Agreement in United States
generally accepted accounting principles (“GAAP”) or regulatory accounting requirements applicable
to the Company and the Company Subsidiaries (C) changes or proposed changes after date of this
Agreement in securities or other laws or regulations of general applicability (excluding banking
laws and banking regulations), (D) changes in the market price or trading volume of the Common
Stock or any other equity, equity-related or debt securities of the Company or the Company
Subsidiaries (but not the underlying reason or reasons for any such change), (E) the effects of
actions or failures to act by the Company or the Company Subsidiaries that are required by this
Agreement, or (F) failure by the Company or any of the Company Subsidiaries to meet internal
projections or forecasts with regard to results of operations or financial condition (but not the
underlying reason or reasons that the projections or forecasts are not met); provided,
however, that in the case of clauses (A), (B) and (C), any
circumstance, change, effect, event or fact shall nevertheless be considered in determining whether
a Company Material Adverse Effect has occurred to the extent that such circumstance, change,
effect, event or fact, individually or in the aggregate, has, or would reasonably be expected to
have, a disproportionate, adverse impact on the business, assets results of operations or financial
condition of the Company and its consolidated Company Subsidiaries taken as a whole relative to
other participants in the United States or in the Commonwealth of Puerto Rico in the industries in
which the Company and the Company Subsidiaries operate.

(c) Authorization. The Company has all corporate power and authority that is
necessary to enable it to enter into this Agreement and carry out the transactions contemplated by
this Agreement. All corporate actions necessary to authorize the Company to enter into this
Agreement and carry out the transactions contemplated by it have been taken, except that, if the
rules of the New York Stock Exchange (“NYSE”) require stockholder approval of the issuance of
Common Stock to the Investor and other investors, that approval has not yet been given. When this
Agreement is executed by the Company, assuming due execution by the Investors, it will be a valid
and binding agreement of the Company, enforceable against the Company in accordance with its terms.
The purchase of the Acquired Common Stock contemplated by this Agreement will not constitute a
Business Combination subject to Section B of Article Tenth of the Company’s Articles of
Incorporation and will not be subject to any statutory or other provisions regarding business
combinations with interested stockholders.

(d) NYSE Required Stockholder Approval. If the rules of the NYSE require stockholder
approval of the issuance of Common Stock to the Investors as contemplated by this Agreement, such
stockholder approval will require the affirmative vote of a majority of the votes cast, provided
that the total votes cast represents over 50% of all the outstanding Common Stock.

(e) Other Investors and Aggregate Sale Price. Subject to Section 4.5, the
Company has entered into, or intends to enter into, agreements (together with this Agreement,
“Investor Agreements”) with investors other than the Investors (“Other Investors”) relating to
purchases of Common Stock at the Per Share Price. The Company is seeking to enter into Investor
Agreements (including this Agreement) relating to sales of Common Stock with a total aggregate sale
price of at least $500 million and not more than (i) $550 million, minus (ii) the purchase price of
the shares that would be issuable on exercise of rights expected to be issued in the Rights
Offering, which Rights Offering will not exceed $35 million in the aggregate.

(f) No Conflict. Neither the execution, delivery and performance by the Company of
this Agreement or of any or all of the Investor Agreements with the Other Investors, nor the
consummation of the transactions contemplated by this Agreement or by any or all of the Investor
Agreements with the Other Investors, will violate, conflict with, result in a breach of, or
constitute a default (or an event which, with notice or lapse of time or both, would constitute a
default) under, (i) the Articles of Incorporation or the By-Laws of the Company, (ii) any agreement
or instrument or obligation to which the Company or any of the Company Subsidiaries is a party or
by which any of them is bound or to which the Company or any of the Company Subsidiaries or any of
their assets or properties may be subject, or (iii) any law, order, rule or regulation of any
governmental or regulatory authorities, agencies, courts, commissions or other entities, whether
federal, state, local or foreign and including such authorities of the Commonwealth of Puerto Rico,
the United States, the United States Virgin Islands, the British Virgin Islands or any other
nation, province, municipality or other political subdivision thereof, or any applicable
self-regulatory organizations (each, a “Governmental Entity”) having jurisdiction over the Company
or any of the Company Subsidiaries, except violations, breaches or defaults that would not
reasonably be expected to have a Company Material Adverse Effect.

(g) Issuance of Acquired Common Stock. When the Company issues the shares of Acquired
Common Stock under Section 1.1, such shares will be duly authorized, validly issued and
non-assessable outstanding shares of Common Stock. The sale of Common Stock as contemplated by
this Agreement and the Investor Agreements with the Other Investors will not give any other person
preemptive rights or other rights to acquire shares of the Company of any class or series. When
shares of Acquired Common Stock are sold to the Investors on the Closing Date as contemplated by
this Agreement, the respective Investors will own such shares free and clear of any liens,
encumbrances or claims of any other persons, other than liens imposed because of acts of the
Investors and restrictions on transfer imposed by applicable securities or banking laws.

(h) Capitalization. The only authorized stock of the Company is 2,000,000,000 shares
of Common Stock and 50,000,000 shares of preferred stock. At the date of this Agreement, the only
outstanding stock is not more than 21,350,000 shares of Common Stock, 2,522,000 shares of Series A
through E preferred stock (with a liquidation preference of $25 per share) and 424,174 shares of
Series G preferred stock (with a liquidation preference of $1,000 per share). In the event the
Company enters into Investor Agreements (including this Agreement) with total aggregate sale
proceeds of between $500 million and $515 million ($550 million minus the expected $35 million
purchase price of the shares that would be issuable on exercise of rights expected to be issued in
the Rights Offering), such Investor Agreements will require the Company to issue no less than
142,857,142 shares of Common Stock and no more than 147,142,858 shares of Common Stock. The only
options, warrants, exchangeable securities or other agreements which require, or which, upon the
passage of time, the payment of money or the occurrence of any other event, may require the Company
to issue any stock of any class or series are (i) options, warrants and employee equity grants that
may entitle the holders to purchase a total of up to 132,000 shares of Common Stock (subject to
adjustment as a result of various occurrences, including the transactions contemplated by this
Agreement and the other Investor Agreements), (ii) the conversion provisions of the Series G
Preferred Stock, which, among other things, give the holders the right to convert the Series G
Preferred Stock into a total of approximately 29,246,000 shares of Common Stock (subject to
adjustment as a result of various occurrences, including the transactions contemplated by this
Agreement and the other Investor Agreements), (iii) a warrant entitling the United States
Department of the Treasury to purchase 389,483 shares of Common Stock (subject to adjustment as a
result of various occurrences, including the transactions contemplated by this Agreement and the
other Investor Agreements) and (iv) the rights of Investors under Investor Agreements. In
addition, the Company has 251,185 shares of Common Stock reserved for issuance under Company
Benefit Plans or for other purposes and the Company expects to issue to the holders of its common
stock as of a day prior to the Closing Date rights that will entitle them to purchase Common Stock
for a per share price equal to the Purchase Price for a total of up to $35 million. The Company
has Previously Disclosed true, correct and complete copies of all instruments and agreements that
govern the terms and conditions of those securities, including all certificates of designation,
warrant agreements and other agreements, as amended through the date of this Agreement.

(i) Consents and Approvals. Neither the execution and delivery of this Agreement by
the Company, nor the completion by the Company of the transactions that are the subject of this
Agreement, requires the consent of, approval by, or a filing or notification by the Company with,
any Governmental Entity, other than (i) filings with the SEC reporting the signing of Investor
Agreements or the consummation of the transactions contemplated thereby; (ii) approval of the Board
of Governors of the Federal Reserve Bank (the “Federal Reserve Board”) of any notice filed by an
Investor pursuant to the Change in Bank Control Act of 1978, as amended; (iii) approval of the
Board Representative described in Section 4.8(g) under the Depository Institution Management
Interlocks Act, in the event that it applies to the Board Representative; (iv) any filings or
notifications that may be required to be made with or given to the Federal Deposit Insurance
Company (the “FDIC”), the Office of the Commissioner of Financial Institutions of the Commonwealth
of Puerto Rico (the “OCFI”) and other banking or insurance regulatory agencies; (v) filing with
NYSE in order to list the shares of Acquired Common Stock in accordance with Section 5.2(f)
and (vi) securities or blue sky laws of the various states. Assuming the Investors’
representations and warranties in Section 3.2(h) are correct, the transactions that are
contemplated by this Agreement qualify for an exemption from the reporting or waiting period
requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) under
Section 7A(c) of the HSR Act.

(j) FirstBank. The Company owns all the outstanding shares of FirstBank. FirstBank
is a commercial bank duly organized and validly existing under the laws of the Commonwealth of
Puerto Rico and is duly licensed by the OCFI. The deposits of FirstBank are insured by the FDIC to
the fullest extent permitted in the Federal Deposit Insurance Act and the rules and regulations of
the FDIC thereunder, and all premiums and assessments required to be paid in connection therewith
have been paid when due.

(k) Subsidiaries. The Company has furnished to the Investors or has Previously
Disclosed a true, correct and complete list of all of its subsidiaries (as the term “subsidiary” is
defined for purposes of the Bank Holding Company Act) as of the date of this Agreement
(individually, a “Company Subsidiary” and, collectively, the “Company Subsidiaries”). Each Company
Subsidiary (including FirstBank) has been duly organized and is validly existing and, to the extent
the concept is applicable, in good standing under the laws of the jurisdiction in which it was
formed. All the shares of stock or other equity interests in each of the Company Subsidiaries,
whether directly or indirectly owned, have been duly authorized and validly issued and, with regard
to stock of corporations or other equity interests in limited liability entities, are fully paid
and non-assessable and are not subject to any preemptive rights and are free and clear of any lien,
adverse right or claim, charge, option, pledge, covenant, title defect, security interest or other
encumbrance of any kind, with no personal liability attaching to the ownership thereof, except
liens, adverse rights or claims, charges, options, pledges, covenants, title defects, security
interests or encumbrances on the Company’s equity interests in Company Subsidiaries other than
FirstBank that do not affect the Company’s control over those Company Subsidiaries and, in the
aggregate, would not reasonably be expected to be materially adverse the Company and the Company
Subsidiaries taken as a whole. Neither the Company nor any of the Company Subsidiaries has issued
any options, warrants, scrips, pre-emptive rights, rights to subscribe, gross-up rights, calls,
commitments or convertible or exchangeable securities, or is a party to any other agreements, which
require, or upon the passage of time, the payment of money or the occurrence of any other event may
require, the Company or any Company Subsidiary to issue or transfer any shares of or other equity
interests in a Company Subsidiary, and there are no registration rights or covenants or transfer or
voting restrictions with respect to any shares of or other equity interests in any of the Company
Subsidiaries.

(l) Company Reports. At least since January 1, 2008, the Company and the Company
Subsidiaries have filed all reports, proxy statements and other documents required to have been
filed with the SEC (the “Company Reports”), including under the Securities Exchange Act of 1934, as
amended (the “Exchange Act”), and have paid all material fees and assessments due and payable in
connection therewith. When they were filed, the Company Reports complied in all material respects
with the applicable rules, regulations and forms promulgated by the SEC and none of the Company
Reports, when filed, contained an untrue statement of a material fact or omitted to state a
material fact necessary in order to make the statements made in it, in light of the circumstances
under which they were made, not misleading. The Company’s Annual Report on Form 10-K for the year
ended December 31, 2010 (the “Company 10-K”) and its Quarterly Report on Form 10-Q for the
quarterly period ended March 31, 2011 (the “March 10-Q”) which were filed with the SEC, including
any documents incorporated by reference in them, each complied in all material respects with the
requirements of the form on which it was filed and, when it was filed, did not contain an untrue
statement of a material fact or omit to state a material fact necessary in order to make the
statements made in it, in light of the circumstances under which they were made, not misleading.
As of the date of this Agreement, there are no outstanding comments from the SEC with respect to
any Company Report other than oral inquiries regarding the accounting for and presentation in the
consolidated financial statements and disclosures made in those consolidated financial statements
regarding the February 2011 sale of loans from FirstBank to a joint venture majority owned by PRLP
Ventures LLC. No executive officer of the Company has failed in any respect to make the
certifications required of him or her under Section 302 or 906 of the Sarbanes-Oxley Act of 2002.

(m) Controls and Procedures. The records, systems, controls, data and information of
the Company and the Company Subsidiaries are recorded, stored, maintained and operated under means
(including any electronic, mechanical or photographic process, whether computerized or not) that
are under the exclusive ownership and direct control of the Company, the Company Subsidiaries or
their accountants (including all means of access thereto and therefrom), except for any
nonexclusive ownership and nondirect control that would not reasonably be expected to have a
material adverse effect on the system of internal accounting controls described below. The Company
(i) has implemented and maintains disclosure controls and procedures (as defined in Rule 13a-15(e)
under the Exchange Act) to ensure that material information relating to the Company, including its
consolidated Company Subsidiaries, is made known to the chief executive officer and the chief
financial officer of the Company by others within those entities, and (ii) has disclosed, based on
its most recent evaluation prior to the date of this Agreement, to the Company’s outside auditors
and the audit committee of the Board of Directors (A) any significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting (as defined in
Rule 13a-15(f) under the Exchange Act) that are reasonably likely to adversely affect the Company’s
ability to record, process, summarize and report financial information, and (B) any fraud, whether
or not material, that involves management or other employees who have a significant role in the
Company’s internal controls over financial reporting. As of the date of this Agreement, no officer
of the Company has knowledge of any reason that its outside auditors and its chief executive
officer and chief financial officer shall not be able to give the certifications and attestations
required pursuant to the rules and regulations adopted pursuant to Section 404 of the
Sarbanes-Oxley Act of 2002, without qualification, when next due. Since December 31, 2008, (A)
neither the Company nor any of the Company Subsidiaries nor, to the knowledge of the Company, any
director, officer, employee, auditor, accountant or representative of the Company or any of the
Company Subsidiaries, has received or otherwise had or obtained knowledge of any material
complaint, allegation, assertion or claim, whether written or oral, regarding the accounting or
auditing practices, procedures, methodologies or methods of the Company or any of the Company
Subsidiaries or their respective internal accounting controls, including any material complaint,
allegation, assertion or claim that the Company or any of the Company Subsidiaries has engaged in
questionable accounting or auditing practices, and (B) no attorney representing the Company or any
of the Company Subsidiaries, whether or not employed by the Company or any of the Company
Subsidiaries, has reported under Part 205 of the SEC Rules (17 CFR §205.1, et.seq.) evidence of a
material violation of securities laws, breach of fiduciary duty or similar violation by the Company
or any of its officers, directors, employees or agents to the Board of Directors or any committee
thereof or to any director or officer of the Company. The management of the Company has, at least
since January 1, 2006, performed the evaluation of the effectiveness, as of the end of each fiscal
year, of the Company’s internal control over financial reporting required by SEC Rule 13a-15(c).
The evaluation as of December 31, 2010 did not disclose any material weaknesses.

(n) Financial Statements. Each of the consolidated balance sheets of the Company and
the Company Subsidiaries and the related consolidated statements of income, stockholders’ equity
and cash flows, together with the notes thereto, included in the Company 10-K, and the unaudited
consolidated balance sheets of the Company and the Company Subsidiaries as of March 31, 2011 and
the related consolidated statements of income, stockholders’ equity and cash flows for the period
ending March 31, 2011, together with the notes thereto, included in the March 10-Q, (the “Interim
Financials” and, collectively, the “Company Financial Statements”), (i) have been prepared from,
and are in accordance with, the books and records of the Company and the Company Subsidiaries, (ii)
complied as to form, as of their respective filing dates, in all material respects with applicable
accounting requirements and with the published rules and regulations of the SEC with respect
thereto, (iii) have been prepared in accordance with GAAP applied on a consistent basis and
(iv) present fairly in conformity with GAAP in all material respects the consolidated financial
position of the Company and the Company Subsidiaries at the dates and the consolidated results of
operations, changes in stockholders’ equity and cash flows of the Company and the Company
Subsidiaries for the periods stated therein (subject to the absence of notes and year-end audit
adjustments in the case of the Interim Financials).

(o) Absence of Undisclosed Liabilities. Neither the Company nor any of the Company
Subsidiaries has any liabilities, contingent or otherwise, that would be required to be reflected
on, or disclosed in notes to, consolidated financial statements of the Company and the Company
Subsidiaries prepared in accordance with GAAP, other than (i) liabilities reflected on the
consolidated balance sheet of the Company and the Company Subsidiaries at March 31, 2011 included
in the March 10-Q, (ii) liabilities disclosed in the notes to the financial statements in the
Company 10-K or the March 10-Q, (iii) liabilities that, because they were not material, were not
required by GAAP to have been reflected on the consolidated balance sheet of the Company and the
Company Subsidiaries at March 31, 2011 or disclosed in the notes to the financial statements
included in the Company 10-K or the March 10-Q, (iv) contingent obligations and contingent
liabilities disclosed in the management’s discussion and analysis of financial condition and
results of operations included in the Company 10-K or the March 10-Q, (v) contingent liabilities
not required by GAAP to be reflected in, or described in notes to, the Company’s financial
statements and not required by applicable SEC rules to be described in the management’s discussion
and analysis of financial condition and results of operations included in the Company 10-K or the
March 10-Q or (vi) liabilities arising in the ordinary course of the conduct by the Company and the
Company Subsidiaries of their respective businesses since March 31, 2011.

(p) Absence of Certain Changes. Since December 31, 2010, (i) the Company and the
Company Subsidiaries, including FirstBank, have conducted their businesses in the ordinary course
and in the same manner in which they were being conducted during the period immediately prior to
December 31, 2010, (ii) there has not been a Material Adverse Change in the financial condition,
results of operations, business or prospects of the Company and the Company Subsidiaries taken as a
whole and (iii) nothing has occurred that has had or is likely to have a Company Material Adverse
Effect. A “Material Adverse Change” (x) in the financial condition of the Company and the Company
Subsidiaries will occur between two dates if between those dates there is a material reduction of
the Company’s and the Company Subsidiaries’ consolidated working capital, net worth or tangible net
worth, a material increase in their consolidated current liabilities (other than due to the conduct
of business in the ordinary course) or a material increase in their consolidated total liabilities
(other than due to the conduct of business in the ordinary course), and (y) in the results of
operations of the Company and the Company Subsidiaries during a period will occur if that period
consists of one or more full fiscal quarters and during that period there is a material reduction
in its and its subsidiaries’ consolidated total revenues, net income before income taxes, net
income, or earnings before interest, taxes, depreciation and amortization compared both with the
same period of the preceding fiscal year and with the immediately preceding period of the same
number of fiscal quarters. However, a change due wholly or primarily to any of the conditions or
occurrences referred to in clauses (A) through (F) of Section 3.1(b) is not
a Material Adverse Change (which clauses shall be read to incorporate the proviso applicable to
clauses A through C in Section 3.1(b)).

(q) Compliance with FDIC Order, OCFI Order and Federal Reserve Agreement. The capital
of the Company and of FirstBank, supplemented by proceeds totaling at least $500 million of the
sales of Common Stock under this and other Investor Agreements and the conversion of the Series G
Preferred Stock into Common Stock, will be sufficient to meet any applicable minimum capital
requirement imposed by statute, regulation or Governmental Entity, including any requirements as to
the capitalization of FirstBank contained in or arising out of the consent order dated June 3, 2010
issued by the FDIC (the “FDIC Consent Order”) and the simultaneous order issued by the OCFI
requiring compliance with the FDIC Consent Order (the “OCFI Order”) or as to the capitalization of
the Company contained in or arising out of the agreement dated June 4, 2010 between the Company and
the Federal Reserve Bank of New York (the “Federal Reserve Agreement”) and any capital plan
approved in connection therewith and in effect.

(r) Compliance with Laws. Each of the Company, FirstBank, and each of the other
Company Subsidiaries has at all times complied, and currently is complying, with, and the condition
and use of its assets and properties has not violated or infringed and does not currently violate
or infringe in any material respects, any applicable United States domestic, federal, state or
local, any applicable Commonwealth of Puerto Rico, or any applicable foreign, laws, regulations,
rules, judgments, injunctions and decrees, including, to the extent they are applicable to the
Company or Company Subsidiaries, the Troubled Asset Relief Program, the Emergency Economic
Stabilization Act of 2008, the Sarbanes-Oxley Act of 2002, the Equal Credit Opportunity Act, the
Fair Housing Act, the Community Reinvestment Act, the Home Mortgage Disclosure Act, the Uniting and
Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism
(USA PATRIOT) Act of 2001, all other applicable fair lending laws or other laws relating to
discrimination and the Bank Secrecy Act, except to the extent of failures to comply, violations or
infringements that would not reasonably be expected to result in actions against the Company or
Company Subsidiaries that would, in the aggregate, interfere in a material respect with the
businesses of the Company and the Company Subsidiaries or result in monetary penalties against the
Company or Company Subsidiaries that would be material to the Company and the Company Subsidiaries
taken as a whole. Insofar as any officer of the Company is aware, none of the Company or any of
the Company Subsidiaries is under investigation with respect to, or has been threatened to be
charged with or given notice of any material violation of, any such laws, regulations, rules,
judgments, injunctions or decrees. FirstBank is the only Company Subsidiary that is subject to the
Community Reinvestment Act. FirstBank has a Community Reinvestment Act rating of “satisfactory” or
better.

(s) Licenses and Permits. The Company and the Company Subsidiaries have all material
licenses and permits from Governmental Entities that are required at the date of this Agreement to
enable them to conduct their businesses as they currently are being conducted. To the knowledge of
the Company, no suspension or cancellation of any such licenses or permits is pending or
threatened.

(t) Litigation. Neither the Company nor any of the Company Subsidiaries is a party to
(i) any legal proceeding that the Company would be required to disclose under Item 103 of SEC
Regulation S-K in a filing at the date of this Agreement or the Closing Date to which that Item
applies, other than legal proceedings disclosed in the Company 10-K, or in a report on Form 8-K
filed with the SEC since December 31, 2010, or (ii) any suit or governmental proceeding that seeks
to prevent the Company from completing the transactions that are the subject of this Agreement or
any of the other Investor Agreements, nor, to the best of the knowledge of any officer of the
Company, has any suit or governmental proceeding which seeks to prevent the Company from completing
the transactions that are the subject of this Agreement been threatened.

(u) Tax Matters. Each of the Company and the Company Subsidiaries has timely filed
when due (taking account of timely filed extensions) all Tax Returns which it has been required to
file and has timely paid or has timely withheld and remitted all Taxes shown on any Tax Return.
All such Tax Returns are true, correct and complete in all material respects and accurately reflect
in all material respects all Taxes required to have been paid, except to the extent of items that
may be disputed by applicable taxing authorities but for which there is substantial authority to
support the position taken by the Company or the Company Subsidiary and which have been adequately
reserved against in accordance with GAAP on the consolidated balance sheet at December 31, 2010
included in the Company 10-K. No Tax lien has been filed by any taxing authority against the
Company or any of the Company Subsidiaries or any of their assets, other than properties acquired
through foreclosure or similar processes and held for sale. Except as Previously Disclosed, no
Federal, Commonwealth, United States Virgin Islands, foreign, state or local audits or other
administrative proceedings or court proceedings in any jurisdiction with regard to Taxes are
currently pending or threatened with regard to the Company or any of its the Company Subsidiaries.
Neither the Company nor any of the Company Subsidiaries (i) is a party to any agreement providing
for the allocation or sharing of Taxes, (ii) has participated in or cooperated with an
international boycott as that term is used in Section 999 of the Internal Revenue Code of 1986, as
amended (the "Code"), or (iii) is liable as a transferee, a successor or otherwise for any Tax
incurred by any other person. There is no material intercompany income or gain which may in the
future become taxable to the Company, whether on disposition of particular assets or Company
Subsidiaries or otherwise. Except as Previously Disclosed, no Tax Return of the Company or any of
the Company Subsidiaries is the subject of an audit by any taxing authority (including any state or
local taxing authority) in the Commonwealth of Puerto Rico, the United States, the U.S. Virgin
Islands or any other nation. All deficiencies asserted or assessments made as a result of any Tax
audits that are not being contested in good faith by appropriate proceedings and for which
appropriate reserves have been established have been paid in full. At least since January 1, 2006,
no claim has been made by an authority in a jurisdiction where the Company or any of the Company
Subsidiaries does not file a Tax Return that the Company or any of the Company Subsidiaries is or
may be subject to taxation by that jurisdiction. Except as Previously Disclosed, neither the
Company nor any Company Subsidiary (i) has waived any statute of limitations with respect to Taxes
or agreed to any extension of time with respect to a Tax assessment or deficiency, in each case,
that is still in effect, or has pending a request for any such extension or waiver or (ii) has or
has ever had a permanent establishment in any country other than the country of its organization,
or is or has ever been subject to Tax in a jurisdiction outside the country of its organization.
The Company is not a “controlled foreign corporation” within the meaning of Section 957 of the
Code, nor will it become a “controlled foreign corporation” as a result of the transactions
contemplated by this Agreement. Neither the Company nor any of the Company Subsidiaries is (i) a
passive foreign investment company within the meaning of Section 1297 of the Code or (ii) a
shareholder, directly or indirectly, in such a passive foreign investment company. There are no
current limitations on the utilization by the Company or any of the Company Subsidiaries of its
respective net operating loss carryforwards under any applicable Tax law, including Section 382 of
the Code (or any similar provision of state, local or non-U.S. law). The transactions described
herein occurring on the Closing Date and any other transactions contemplated by this Agreement will
not result in a limitation on the utilization of the Company’s or FirstBank’s net operating loss
carryforwards under any applicable provision of Puerto Rico income Tax law. The net operating loss
carryforward of FirstBank as of December 31, 2010 as a result of losses that have been or will be
reflected on FirstBank’s Puerto Rico income tax returns (at least some of which are or will be
subject to audit) is at least $550,000,000. For the purposes of this Agreement, the term “Taxes”
means (1) all Commonwealth of Puerto Rico, U.S. Virgin Islands, British Virgin Islands, U.S.
federal, state, local, foreign or other taxes of any kind (together with any and all interest,
penalties, additions to tax and additional amounts imposed with respect thereto) imposed by any
Governmental Entity, including taxes on or with respect to income, franchise, windfall or other
profits, gross receipts, property, sales, use, capital stock, payroll, employment, unemployment,
social security, workers’ compensation or net worth, and taxes in the nature of excise,
withholding, ad valorem or value added, (2) liability for the payment of any amounts of the type
described in clause (1) as a result of being or having been a member of an affiliated,
consolidated, combined or unitary group, and (3) liability for the payment of any amounts as a
result of being party to any tax sharing agreement or as a result of any express or implied
obligation to indemnify any other person with respect to the payment of amounts of the type
described in clause (1) or (2). For the purposes of this Agreement, the term “Tax Return” means
any and all returns and reports (including elections, declarations, disclosures, schedules,
estimates and information returns and any amendments thereto) supplied or required to be supplied
to any Governmental Entity in connection with Taxes.

(v) Environmental Matters. Except as would not reasonably be expected, in aggregate,
to have a Company Material Adverse Effect, (i) the Company and the Company Subsidiaries have all
environmental permits which are necessary to enable them to conduct their businesses as they are
being conducted on the date of this Agreement without violating any Environmental Laws,
(ii) neither the Company nor any of the Company Subsidiaries has received any notice of material
noncompliance or material liability under any Environmental Law, (iii) neither the Company nor any
of the Company Subsidiaries has performed any acts, including, but not limited to, releasing,
storing or disposing of hazardous materials, there is no condition on any property owned or leased
by the Company or a Company Subsidiary, and there was no condition on any property formerly owned
or leased by the Company or a Company Subsidiary while the Company or a Company Subsidiary owned or
leased that property, that could result in liability by the Company or a Company Subsidiary under
any Environmental Law and (iv) neither the Company nor any of the Company Subsidiaries is subject
to any order of any Governmental Entity requiring the Company or any of the Company Subsidiaries to
take, or refrain from taking, any actions in order to comply with any Environmental Law and no
action or proceeding seeking such an order is pending or, insofar as any officer of the Company or
any of the Company Subsidiaries is aware, threatened against the Company or any of the Company
Subsidiaries. As used in this Agreement, the term "Environmental Law” means any United States,
Puerto Rico or other national, state or local law, rule, regulation, guideline or other legally
enforceable requirement of a Governmental Entity relating to protection of the environment or to
environmental conditions which affect human health or safety.

(w) Labor Matters. No employees of the Company or Company Subsidiaries are
represented by any labor union nor are there any collective bargaining agreements otherwise in
effect. There is no pending demand by any union or employee group to be recognized or certified as
the bargaining representative for any of the Company’s or the Company Subsidiaries’ employees, and
there are no proceedings seeking recognition or certification of that type pending before the
National Labor Relations Board or any other Governmental Entity in the United States, Puerto Rico
or elsewhere.

(x) Company Benefit Plans.

(i) The Company has Previously Disclosed all benefit plans, agreements, commitments,
practices or arrangements of any type maintained or sponsored by the Company or any Company
Subsidiary for its current and former employees, directors and consultants and the
compensation paid to all its directors, to its Chief Executive Officer, its Chief Financial
Officer, and its three most highly compensated officers other than its Chief Executive
Officer and its Chief Financial Officer who were serving as officers at December 31, 2011.
“Company Benefit Plans” means all benefit and compensation plans, agreements, commitments,
practices or arrangements of any type maintained or sponsored by the Company or any Company
Subsidiary for its current and former employees, directors and individual consultants.

(ii) Except as would not reasonably be expected to result in a liability that would be
material to the Company and the Company Subsidiaries taken as a whole, (i) each Company
Benefit Plan that is required to be registered with, or approved by, a Governmental Entity
in the Commonwealth of Puerto Rico, the United States or any other jurisdiction has been so
registered with or approved by that Governmental Entity, and (ii) each Company Benefit Plan
has been maintained in all material respects in accordance with its terms and any applicable
provisions of law (including, if applicable, the U.S. Employee Retirement Income Security
Act of 1974, as amended (“ERISA”), the Code, the Internal Revenue Code of New Puerto Rico,
the Troubled Asset Relief Program, and the Emergency Economic Stabilization Act of 2008).

(iii) No Company Benefit Plan is (x) a pension plan (of the type described in Section
3(2) of ERISA) subject to statutory minimum funding requirements under Title IV of ERISA,
Section 412 of the Code, or similar law; (y) a “multiemployer plan” (of the type described
in Section 3(37) of ERISA), or (z) an “employee welfare plan” (of the type described in
Section 3(1) of ERISA) providing benefits, including death or medical benefits, beyond
termination of service or retirement other than coverage mandated by the Consolidated
Omnibus Budget Reconciliation Act of 1985, as amended, or similar law, and at the sole
expense of the participant or the participant’s beneficiary. Neither the Company nor any
Company Subsidiary would reasonably be expected to have any liability with respect to any
plan described in (x), (y), or (z) of this subsection or otherwise as a result of any trade
or business that is or during the past six years has been treated as a single employer with
the Company or any Company Subsidiary under Section 414(b), (c), (m) or (o) of the Code or
Section 4001(b) of ERISA.

(iv) Neither the execution of this Agreement nor the consummation of the transactions
contemplated by this Agreement will give rise to a change in control under, or result in the
breach or the violation of, or the acceleration of any right under, or result in any
additional rights, or the triggering of any anti-dilution adjustment under an equity plan
sponsored by the Company or any of the Company Subsidiaries or an employment agreement or
other contract or agreement to which the Company or any of the Company Subsidiaries is a
party.

(v) Neither the Company nor any of the Company Subsidiaries has a contract, plan or
commitment, whether legally binding or not, to create any additional Company Benefit Plan or
to modify any existing Company Benefit Plan in a manner that would increase materially the
expense of maintaining such Company Benefit Plan above the level of the expense incurred
therefore for the most recent fiscal year.

(y) Investment Company or Investment Adviser. Neither the Company nor any of the
Company Subsidiaries is required to be registered as an investment company under the Investment
Company Act of 1940, as amended, or to be registered under the Investment Advisers Act of 1940, as
amended.

(z) Compliance with Banking Laws and Regulations. Neither the Company nor any of the
Company Subsidiaries (including FirstBank) (i) is subject to (or has been advised that a
Governmental Entity that regulates banking activities in any location in which the Company or any
Company Subsidiary conducts banking activities (including the FDIC, the OCFI and the Federal
Reserve) (each a “Bank Regulatory Agency”) is considering issuing, initiating or ordering) any
cease-and-desist or similar order, or any enforcement action commenced, by any Bank Regulatory
Agency or (ii) is a party to any written agreement, consent agreement or memorandum of
understanding with, or any commitment letter or written undertaking to, any Bank Regulatory Agency,
and no resolution of the Board of Directors of the Company or any of the Company Subsidiaries
(including FirstBank) is in effect that was adopted at the request of a Bank Regulatory Agency that
restricts in any material respect the conduct of its business or that relates in a material manner
to its capital adequacy, its liquidity and funding policies and practices, its ability to pay
dividends, its credit, risk management or compliance policies, its internal controls, its
management or its operations or business, other than the FDIC Consent Order, the OCFI Order, the
Federal Reserve Agreement and a confidential agreement dated September 28, 2010 with a Bank
Regulatory Agency. The Company and each of the Company Subsidiaries is in compliance in all
material respects with all agreements, commitments and undertakings it has made to a Governmental
Entity that are currently in effect (including the FDIC Consent Order, the OCFI Order and the
Federal Reserve Agreement) and neither the Company nor any of the Company Subsidiaries has received
any notice from any Bank Regulatory Agency indicating that either the Company or any of the Company
Subsidiaries is not in compliance in all material respects with any such agreement, commitment or
undertaking.

(aa) Compliance with Mortgage Laws and Sale of Mortgage Loans. The Company and the
Company Subsidiaries have complied in all material respects with (i) all requirements of applicable
laws and governmental regulations with respect to the origination, purchase, sale, insuring or
servicing of or filing of claims in connection with mortgage loans, including all laws and
governmental regulations with respect to documentation in connection with the origination,
processing, underwriting (including credit approval), purchase and servicing of mortgage loans,
real estate settlement procedures, consumer protection, truth in lending, fair housing, transfers
of servicing, collection practices, equal credit opportunity and adjustable rate mortgages, (ii)
with regard to mortgage loans any of them has sold to any Agency, any agreements with, or
applicable rules, regulations, guidelines or other requirements of, any Agency to which the
mortgage loans were sold, in each case, except failures to comply that would not reasonably be
expected, in aggregate, to have a Company Material Adverse Effect, (iii) the responsibilities and
obligations relating to mortgage loans set forth in any agreement between the Company or any of the
Company Subsidiaries and any such Agency, Loan Investor or Insurer, and (iv) the terms and
provisions of any mortgage or other collateral documents and other loan documents with respect to
each mortgage loan, in the case of this clause (iv) only, except as would not cause a
Company Material Adverse Effect.  Neither the Company nor any of the Company
Subsidiaries has received a written claim from any Agency, Loan Investor or Insurer to the effect
that the Company or any of the Company Subsidiaries has failed to comply in any material respect
with applicable underwriting standards or guidelines with respect to mortgage loans sold by the
Company or any of the Company Subsidiaries to an Agency or Loan Investor or with respect to any
sale of mortgage servicing rights, or a written notice from any Agency, Loan Investor or Insurer
restricting the activities (including commitment authority) of the Company or any of the Company
Subsidiaries or terminating or giving notice of intent to terminate its relationship with the
Company or any of the Company Subsidiaries because of poor performance, poor loan quality or
concern with respect to the Company’s or any of the Company Subsidiaries’ compliance with laws.
For purposes of this Section 3.1(aa):

(i) “Agency ” shall mean the Federal Housing Administration, the Federal Home Loan
Mortgage Corporation, the Federal National Mortgage Association, the Government National
Mortgage Association, or any other federal or state agency with authority to (i) determine
any investment, origination, lending or servicing requirements with regard to mortgage loans
originated, purchased or serviced by the Company or any of the Company Subsidiaries or (ii)
originate, purchase, or service mortgage loans, or otherwise promote mortgage lending,
including, without limitation, state and local housing finance authorities;

(ii) “Loan Investor ” shall mean any person (including an Agency) having a beneficial
interest in any mortgage loan originated, purchased or serviced by the Company or any of the
Company Subsidiaries or a security backed by or representing an interest in any such
mortgage loan; and

(iii) “Insurer ” shall mean a person who insures or guarantees for the benefit of the
mortgagee all or any portion of the risk of loss upon borrower default on any of the
mortgage loans originated, purchased or serviced by the Company or any of the Company
Subsidiaries, including the Federal Housing Administration, the United States Department of
Veterans’ Affairs, the Rural Housing Service of the U.S. Department of Agriculture and any
private mortgage insurer, and providers of hazard, title or other insurance with respect to
such mortgage loans or the related collateral.

(bb) Risk Management. The Company and the Company Subsidiaries have in place risk
management policies and procedures sufficient in scope and operation to provide reasonable
protection against risks of the type and in amounts reasonably expected to be incurred by entities
that are similar to the Company and the Company Subsidiaries in size and in the lines of business
in which they are engaged. All material derivative instruments entered into by the Company or the
Company Subsidiaries for their own accounts were entered into (i) in the ordinary course of
business only for the purposes of mitigating identified risks, (ii) in accordance with prudent
practices and in all material respects with all applicable laws, rules, regulations and regulatory
policies, and (iii) with counterparties that, at the time, the Company or the applicable Company
Subsidiary believed to be financially responsible. Each such material derivative instrument
constitutes a valid and legally binding obligation of the Company or one or more of the Company
Subsidiaries, enforceable in accordance with its terms and, to the knowledge of the Company,
neither the Company nor any of the Company Subsidiaries, nor any other party thereto, is in
material breach of or has materially defaulted under any such agreement or arrangement.

(cc) Patriot Act, Office of Foreign Asset Controls; Anti-Money Laundering. The
operations of the Company and the Company Subsidiaries are being conducted in compliance in all
material respects with applicable financial recordkeeping, reporting and other requirements of the
Currency and Foreign Transactions Reporting Act of 1970, as amended, the United and Strengthening
America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001,
any applicable order or regulation issued by the Office of Foreign Assets Control of the U.S.
Department of the Treasury (“OFAC”), or any other applicable anti-money laundering or
anti-terrorist-financing statutes, rules or regulations of any jurisdictions, and no action or
proceeding by or before any Governmental Entity alleging violations of anti-money laundering
statutes or anti-terrorist financing statutes by the Company or any of the Company Subsidiaries is
pending or, to the knowledge of the Company, threatened, except, in each case, as would not
reasonably be expected, in aggregate, to have a Company Material Adverse Effect. None of the
Company or any of the Company Subsidiaries has, since December 31, 2008, nor to the knowledge of
the Company has any other person on behalf of the Company or any of the Company Subsidiaries that
qualifies as a “financial institution” under U.S. anti-money laundering laws, knowingly acted, by
itself or in conjunction with another, in any act in connection with the concealment of any
currency, securities or other proprietary interest that is the result of a felony as defined in
U.S. anti-money laundering laws (“Unlawful Gains”), nor knowingly accepted, transported, stored,
dealt in or brokered any sale, purchase or any transaction of any other nature for Unlawful Gains.
Each of the Company and, to the extent it qualifies as a “financial institution” under U.S.
anti-money laundering laws, any of the Company Subsidiaries has implemented in all material
respects such anti-money laundering mechanisms and kept and filed all material reports and other
necessary material documents as required by, and otherwise complied in all material respects with,
U.S. anti-money laundering laws and rules and regulations thereunder. None of the Company or any
of the Company Subsidiaries, nor any of their respective directors, officers, agents, employees or
any other persons acting on their behalf, will knowingly directly or indirectly lend, contribute or
otherwise make available any funds to any subsidiary, joint venture partner or other person or
entity for the purpose of financing the activities of any person currently subject to U.S.
sanctions administered by OFAC.

(dd) Foreign Corrupt Practices Act. None of the Company or any of the Company
Subsidiaries, nor any of their respective directors, officers, agents, employees or any other
persons acting on their behalf (i) has violated the Foreign Corrupt Practices Act, 15 U.S.C. §
78dd-1 et seq., as amended, or any other similar applicable foreign, federal, or state legal
requirement, including making or providing, or causing to be made or provided, directly or
indirectly, any payment or thing of value to a foreign official, foreign political party, candidate
for office or any other person knowing that the person shall pay or offer to pay the foreign
official, party or candidate, for the purpose of influencing a decision, inducing an official to
violate their lawful duty, securing any improper advantage, or inducing a foreign official to use
his or her influence to affect a governmental decision, (ii) has paid, accepted or received any
unlawful contributions, payments, expenditures or gifts, or (iii) has violated or operated in
noncompliance with any export restrictions, anti-terrorism law or regulation, anti-boycott
regulations or embargo regulations.

(ee) Insurance. The Company and each of the Company Subsidiaries is presently
insured, and during each of the past three calendar years (or during such lesser period of time as
the Company has owned such subsidiary) has been insured, for reasonable amounts with financially
sound and reputable insurance companies against such risks as companies engaged in a similar
business would, in accordance with good business practice, customarily be insured.

(ff) Core Deposits and Certificates of Deposits. As of the date hereof, FirstBank has
at least $3,475,000,000 in core deposits (including money market, demand, checking, savings and
transactional accounts and excluding secured governmental deposits and certificates of deposits)
and at least $1,825,000,000 in certificates of deposits, excluding governmental and brokered
deposits.

(gg) Loans to Affiliates; Loans to Directors and Officers. Neither the Company nor
any of the Company Subsidiaries is a party to any loan, loan agreement, note or borrowing
arrangement (including leases, credit enhancements, commitments, guarantees and interest-bearing
liabilities) (each, a “Loan”) with any director or executive officer of the Company or any of the
Company Subsidiaries or shareholder of the Company that beneficially owns five percent or more of
the voting common stock of the Company. All Loans with any executive officer of the Company or any
of the Company Subsidiaries or shareholder of the Company are made in compliance with the
applicable requirements of the Federal Reserve Board’s Regulation O.

(hh) Compliance with Securities Laws. Neither the Company nor any person acting on
its behalf has taken any action (including, offering any securities of the Company under
circumstances which would require the integration of such offering with the offering of any of the
securities to be issued pursuant to this Agreement or any other Investor Agreement with any Other
Investors for purposes of the Securities Act and the rules and regulations of the SEC promulgated
thereunder) which might subject the offering, issuance or sale of any of the securities to be
issued pursuant to this Agreement or any other Investor Agreement with any Other Investors to the
registration requirements of the Securities Act or that would cause the sale of Common Stock under
this and the other Investor Agreements not to be eligible for the exemption from the registration
requirements of the Securities Act contained in Section 4(2) of that Act.

(ii) Commitments and Contracts. Each agreement to which the Company or any Company
Subsidiary is a party which is a “material contract” within the meaning of Item 601(b)(10) of
Regulation S-K (each, a “Company Significant Agreement”) is valid and binding on the Company and
the Company Subsidiaries, as applicable, and, and insofar as any officer of the Company is aware,
is valid and binding on the other party or parties to it, and is in full force and effect. The
Company and each of the Company Subsidiaries, as applicable, are in all material respects in
compliance with and have in all material respects performed all obligations required to be
performed by them to date under each Company Significant Agreement. Neither the Company nor any of
the Company Subsidiaries knows of, or has received notice of, any material violation or default (or
any condition which with the passage of time or the giving of notice would cause such a violation
of or a default) by the Company or any Company Subsidiary under any Company Significant Agreement.
To the knowledge of the Company, as of the date of this Agreement, there are no material
transactions or series of related transactions, agreements, arrangements or understandings, nor are
there any currently proposed material transactions, or series of related transactions between the
Company or any Company Subsidiaries, on the one hand, and the Company, any current or former
director or executive officer of the Company or any Company Subsidiaries or any person who
beneficially owns 5% or more of the Common Shares (or any of such person’s immediate family members
or affiliates) (other than Company Subsidiaries), on the other hand.

(jj) Properties and Leases. The Company and the Company Subsidiaries have good and
marketable title to all real properties and good title to all other properties and assets owned by
them (other than any assets the Company or any of the Company Subsidiaries has repossessed), in
each case, free from Liens that would affect the value thereof or interfere with the use made or to
be made thereof by them in any material respect. The Company and the Company Subsidiaries own or
lease all properties that are necessary to their operations as now conducted. All leases of real
property and all other leases material to the Company or any of the Company Subsidiaries pursuant
to which the Company or any such Company Subsidiary, as lessee, leases real or personal property
are valid and effective in accordance with their respective terms, and there is not, under any such
lease, any existing default by the Company or such Company Subsidiary or any event which, with
notice or lapse of time or both, would constitute such a default except for such as would not
reasonably be expected to have a Company Material Adverse Effect.

(kk)  Intellectual Property Rights.  

(i) The Company and the Company Subsidiaries own or possess adequate rights or licenses
to use all material Intellectual Property rights (“Intellectual Property Rights”) necessary
to conduct their business as conducted on the date of this Agreement and as presently
contemplated to be conducted in the future.  To the knowledge of the Company, no product or
service of the Company or the Company Subsidiaries infringes the Intellectual Property
Rights of others.  The Company and the Company Subsidiaries have not received notice of any
claim being made or brought, or, to the knowledge of the Company, being threatened, against
the Company or any of the Company Subsidiaries (i) regarding their Intellectual Property
Rights that are necessary to conduct their business as conducted on the date of this
Agreement and as presently contemplated to be conducted in the future, or (ii) that the
products or services of the Company or the Company Subsidiaries infringe the Intellectual
Property Rights of others.  The computers, computer software, firmware, middleware, servers,
workstations, routers, hubs, switches, data communications lines, and all other information
technology equipment, and all associated documentation used in the business of the Company
and the Company Subsidiaries (the “IT Assets”) operate and perform in all material respects
in accordance with their documentation and functional specifications and otherwise as
required in connection with the business. To the Company’s knowledge, no person has gained
unauthorized access to the IT Assets. The Company and the Company Subsidiaries have
implemented reasonable backup and disaster recovery technology consistent with industry
practices. The Company and the Company Subsidiaries take reasonable measures, directly or
indirectly, to ensure the confidentiality, privacy and security of customer, employee and
other confidential information. The Company and the Company Subsidiaries have complied with
all internet domain name registration and other requirements of internet domain registrars
concerning internet domain names that are used in the business.  Without limiting the
foregoing, the Company and the Company Subsidiaries (A) own or have the valid right to use
all the names that are material to the conduct of their businesses or the maintenance of
their customer goodwill, including the name “FirstBank”, in all applicable jurisdictions,
free and clear of all Liens and (B) have not granted to any third party, by license or
otherwise, any right or interest in or to use any such name other than in connection with
relationships between those third parties and the Company or Company Subsidiaries.  No third
party has asserted any rights in any geographic area in which it competes with the Company
or a Company Subsidiary to any name that is material to the business of the Company or a
Company Subsidiary with which the third party competes.

(ii) For the purposes of this Agreement, “Intellectual Property” shall mean trademarks,
service marks, brand names, certification marks, trade dress, domain names and other
indications of origin, the goodwill associated with the foregoing and registrations in any
jurisdiction of, and applications in any jurisdiction to register, the foregoing, including
any extension, modification or renewal of any such registration or application; inventions,
discoveries and ideas, whether patentable or not, in any jurisdiction; patents, applications
for patents (including divisions, continuations, continuations in part and renewal
applications), and any renewals, extensions or reissues thereof, in any jurisdiction;
nonpublic information, know-how, trade secrets and confidential information and rights in
any jurisdiction to limit the use or disclosure thereof by any person; writings and other
works, whether copyrightable or not, in any jurisdiction; and registrations or applications
for registration of copyrights in any jurisdiction, and any renewals or extensions thereof;
and any similar intellectual property or proprietary rights.

3.2 Representations and Warranties of the Investors. Each Investor represents and
warrants, severally and not jointly and only with respect to itself, to the Company as follows:

(a) Organization and Power. The Investor is duly organized, validly existing and in
good standing under the laws of the jurisdiction in which it was formed and the Investor is duly
qualified to do business in all jurisdictions where failure to be qualified could reasonably be
expected to affect adversely the Investor’s ability to carry out the transactions that are the
subject of this Agreement. The Investor is an entity advised by an affiliate of Thomas H. Lee
Partners, L.P.

(b) Authorization. The Investor has all power and authority that is necessary to
enable it to enter into this Agreement and carry out the transactions contemplated by this
Agreement. All actions necessary to authorize the Investor to enter into this Agreement and carry
out the transactions contemplated by it have been taken. This Agreement has been duly executed by
the Investor and, assuming due execution by the Company, it is a valid and binding agreement of the
Investor, enforceable against the Investor in accordance with its terms.

(c) No Conflict. Neither the execution and delivery of this Agreement by the Investor
nor the consummation of the transactions contemplated by this Agreement will violate, result in a
breach of, or constitute a default (or an event which, with notice or lapse of time or both, would
constitute a default) under, (i) the certificate of incorporation and bylaws or other
organizational documents of the Investor, (ii) any agreement or instrument to which the Investor or
any of its subsidiaries is a party or by which any of them is bound, or (iii) except as set forth
on Schedule 3.2, any law, or any order, rule or regulation of any Governmental Entity
having jurisdiction over the Investor or any of its subsidiaries, except violations, breaches or
defaults that would not reasonably be expected to affect adversely the Investor’s ability to carry
out the transactions that are the subject of this Agreement when and as contemplated by this
Agreement.

(d) Consents and Approvals. Except as set forth on Schedule 3.2, neither the
execution and delivery of this Agreement by the Investor, nor the completion by the Investor of the
transactions that are the subject of this Agreement, requires the consent of, approval by, or a
filing or notification by the Investor with, any Governmental Entity, other than filings under the
Exchange Act reporting the purchase of Common Stock by the Investor and filings, notifications,
clearances or approvals that may be required to be made or given with or to, or obtained from, the
Federal Reserve Board, the FDIC, the OCFI or any other Governmental Entity, including any banking
or insurance regulatory agency, as a result of its jurisdiction over the Company or any of the
Company Subsidiaries (including FirstBank) or persons who control the Company. At the date of this
Agreement, the Investor does not know of any reason that any Governmental Entity would not give any
required consent to, or approval of, the Investors’ acquiring the Acquired Common Stock as
contemplated by this Agreement. The transactions that are contemplated by this Agreement qualify
for an exemption from the reporting or waiting period requirements of the HSR Act under Section
7A(c) of the HSR Act.

(e) Ownership. The Investor does not own any interest in any institution that would
be a “commonly controlled insured depositary institution” (as that term is defined for purposes of
Section 5(e) of the Federal Deposit Insurance Act) with respect to the Company or any Company
Subsidiary following the Investor’s purchase of the Acquired Common Stock as contemplated by this
Agreement. Except as shown on the signature page of this Agreement, neither the Investor nor any
affiliate of the Investor (other than an affiliate as to which the Investor does not control
decisions regarding the purchase, sale or voting of securities) owns any Common Stock of the
Company.

(f) Financial Capacity. The Investor has, or has legally binding commitments from
equity investors, lenders or both to provide, and the Investor will have on the Closing Date, all
the funds the Investor will require to enable the Investor to pay the purchase price for the
Acquired Common Stock it will be purchasing as described in Section 1.1 when and as
contemplated by this Agreement.

(g) Accredited Investor. The Investor either (i) is an accredited investor, as that
term is defined in SEC Rule 501 under the Securities Act, of the type described in clause (1), (2),
(3), (4) or (7) of that Rule, and has such knowledge and experience in financial and business
matters and in investments similar to the purchase of the Acquired Common Stock that it is capable
of evaluating the merits and risks of its investment in the Acquired Common Stock and of making an
informed investment decision regarding the purchase of the Acquired Common Stock, or (ii) is not a
U.S. person, as that term is defined in SEC Regulation S under the Securities Act and is acquiring
the Acquired Common Stock outside the United States. The Investor is aware that the Acquired
Common Stock is being offered in a transaction not involving a public offering in the United
States, that the offer and sale of the Acquired Common Stock has not been registered under the
Securities Act, and that the Investor may only sell or transfer Acquired Common Stock under the
limited circumstances set forth in Article 7. The Investor will be acquiring the Acquired
Common Stock for investment, and not with a view to distributing it, except that the Investor may
sell Acquired Common Stock, to the extent permitted by Article 7, in transactions
registered under the Securities Act or to qualified institutional investors in transactions that
are exempt as provided in Rule 144A under the Securities Act.

(h) Investment Purpose. The Investor will be acquiring the Acquired Common Stock for
investment (as that term is defined in the rules under the HSR Act) and, assuming the Company’s
representations and warranties in Section 3.1(h) are correct, the acquisition of the
Acquired Common Stock by the Investor as contemplated by this Agreement will not result in the
Investor’s owning 25% or more of the outstanding Common Stock. The Investor is not acting in
concert with any other party to an Investor Agreement with regard to the purchase of Common Stock
and the Investor has no agreements or understandings with any other persons (other than its
agreements with the Company in this Agreement) regarding actions as a stockholder of the Company
after the Closing Date.

(i) Investor’s Decision. The Investor’s decision to enter into this Agreement and to
purchase the Acquired Common Stock it has agreed to purchase was based on the Investor’s or its
adviser’s independent analysis of the merits and risks of an investment in Acquired Common Stock,
taking into account the Investor’s own financial circumstances. The Investor did not rely in
making that decision upon any analysis prepared by, or investment advice received from, the Company
or any financial advisor, placement agent or other person acting on behalf of the Company. The
Investor is, however, relying on the representations and warranties of the Company in this
Agreement in making its decision to purchase Acquired Common Stock.

ARTICLE 4

ACTIONS PRIOR TO THE TRANSACTION

4.1 Stockholder Approval. Unless the NYSE informs the Company that the NYSE rules
(including Rule 312.03 of the listed company rules) do not require (whether because the NYSE
requirement has been satisfied by prior stockholder approvals, or because of an exception, a waiver
or otherwise) approval by the Company’s stockholders of the transactions that are the subject of
the Investor Agreements, within 20 days after the date of this Agreement, the Company will file
with the SEC a preliminary proxy statement relating to a stockholders meeting at which the
Company’s stockholders will be asked to approve the transactions that are the subject of the
Investor Agreements. The Company will include in the proxy statement the recommendation of its
Board of Directors that the Company’s stockholders vote to approve the transactions that are the
subject of the Investor Agreements, unless, and solely to the extent, the Board determines, after
consultation with counsel, that in the exercise of its fiduciary duties it must withdraw or modify
that recommendation. A withdrawal or modification of the recommendation of the Board shall not
affect the obligations of the Company to hold the meeting of the Company’s stockholders
contemplated by this Agreement. The Investors and their counsel shall have the opportunity to
review such preliminary proxy statement in advance of the Company filing such preliminary proxy
statement with the SEC, and to provide comments thereon, which comments the Company shall give due
and reasonable consideration. The Company will provide any comments received from the SEC to the
Investors and their counsel as promptly as practicable upon receipt thereof and shall use its
reasonable best efforts to consult with the Investors and their counsel and, to the extent it is
not unreasonable for it to do so, to resolve and comply with all comments of the staff of the SEC
promptly, and to cause the proxy statement to be filed in definitive form and distributed to the
Company’s stockholders as promptly as practicable, and in any event within five Business Days after
the Company is informed by the staff of the SEC that they have no further comments with regard to
the proxy statement, either by mail or by notice of internet access. The Company will cause the
stockholders meeting to which the proxy statement relates and at which the Company’s stockholders
will be asked to approve the transactions that are the subject of the Investor Agreements to be
held as promptly as practicable and no more than 40 days after the Company distributes the proxy
statement to its stockholders.

4.2  HSR Act Filings.

(a) The purchase of the Acquired Common Stock by the Investors as contemplated by this
Agreement (either alone or together with the purchases of Common Stock by other investors under
Investor Agreements) qualifies for an exemption from the reporting or waiting period requirements
of the HSR Act under Section 7A(c) of the HSR Act. In order to satisfy the requirements of such
exemption, the Investors and the Company will each make as promptly as practicable any filings
they are required to make in connection with such exemption under the HSR Act and such other
antitrust laws with regard to the transactions that are the subject of this Agreement and each of
them will take all reasonable steps within its control (including providing information to the
Federal Trade Commission and the Department of Justice) to ensure the transaction qualifies for
the exemption under the HSR Act. Each of the Investors and the Company will each provide
information and cooperate in all other respects to assist the other of them in ensuring that the
transaction qualifies for the exemption under the HSR Act.

(b) If it is determined by any Governmental Agency that a filing with regard to the
transactions that are the subject of this Agreement is required under the HSR Act (the HSR Act
(notwithstanding the belief of the Company and the Investors that those transactions are exempt
from the reporting and waiting period requirements of the HSR Act) or any other antitrust or
competition laws of any jurisdiction, each of the Investors and the Company will each provide
information and cooperate in all other respects to assist the other of them in making the filing
required under the HSR Act or other antitrust or competition law. The Company will pay the filing
fee that is required with regard to any filing required under the HSR Act or any other antitrust
or competition law.

4.3 Listing of Shares. Promptly after the date of this Agreement, the Company will
file an application with the NYSE to list the shares of Common Stock that it will be issuing under
this Agreement and the other Investor Agreements and the Company will use its best commercially
reasonable efforts to cause those shares to be authorized for listing upon notice of issuance.

4.4 Change of Bank Control Act and Bank Holding Company Act. Each Investor that is
required to file a written notice with the Federal Reserve Board under the Change in Bank Control
Act of 1978, as amended (the “CBCA”) with respect to such Investor’s proposed purchase of Acquired
Common Stock will file that notice within 20 Business Days after the date of this Agreement and
will use its best commercially reasonable efforts, including providing all information reasonably
requested by the Federal Reserve Board and entering into customary passivity commitments, to obtain
as promptly as practicable a written confirmation from the Federal Reserve Board to the effect that
such Investor’s purchase of the Acquired Common Stock and the consummation of the transactions that
are the subject of this Agreement will not result in such Investor or any of its affiliates being
in control of the Company or of FirstBank for purposes of the Bank Holding Company Act or the
Federal Reserve Board’s Regulation Y, or otherwise being subject to regulation as a bank holding
company under that Act. The Company will cooperate with each Investor in all reasonable respects
with regard to such Investor’s efforts to obtain such confirmation from the Federal Reserve Board.
If the Federal Reserve Board requires revisions to the structure of the transactions that are the
subject of this agreement before it will give such confirmation, the Company and the Investors will
cooperate to make the necessary revisions, provided that neither the Company nor the Investors will
be required to revise the structure of those transactions in a way that will impose a “Materially
Burdensome Regulatory Condition ,” defined as any condition, restriction or limitation (other than
passivity commitments or other conditions, restrictions or limitations that are customary for
similarly situated investments, but including, for the avoidance of doubt, any modification,
alteration, deletion or other change to the terms and conditions of the Investor Agreements that
differs from those agreed by and among the parties), arising pursuant to any notice to,
registration, declaration or filing with, exemption or review by, or authorization, order, consent
or approval of, any Governmental Entity, that when used in reference to an Investor’s or the
Company’s obligations hereunder or a condition to an Investor’s or the Company’s obligations
hereunder, is, in the good faith reasonable judgment of such Investor or the Company, as the case
may be, materially burdensome on, or would materially reduce the economic benefits of the
transactions contemplated by this Agreement to, such Investor or the Company or any of their
affiliates.

4.5 Most Favored Terms. The Company will not enter into any Investor Agreement, or
amend any Investor Agreement, with any Other Investor so that such other Investor Agreement is in
any respect more favorable to the Other Investor that is a party to such Investor Agreement than
this Agreement is to the Investors, including with respect to the Per Share Price, or that gives
any Other Investor or group of affiliated Other Investors the right to purchase more shares of
Common Stock than the total number of shares to be purchased by all the Investors, unless the
Company modifies this Agreement so that it provides the Investors with the same rights and benefits
that are provided to the Other Investor under the Investor Agreement to which it is a party (or the
Company offers to modify this Agreement in that manner but the Investors refuse to agree to such
modification). To the extent funds are raised via private placements, the Company shall provide
the Investors with copies of any and all written documents the Company or its representatives
prepare for the purposes of such private placements, including the offering memorandum, and shall
cooperate with the Investors to incorporate the Investors’ reasonable comments provided on a timely
basis regarding any such documents that are finalized after the date of this Agreement prior to
furnishing such documents to the participants in such private placements.

4.6 Notice of Adverse Occurrences. The Company shall promptly provide the Investors
with written notice of the occurrence of any circumstance, change, effect, event, fact or
development occurring between the date hereof and the Closing Date and relating to the Company or
any of the Company’s Subsidiaries of which the Company has knowledge and which (a) causes any
representation and warranty in Section 3.1 to cease to be correct, (b) could give rise to a
Material Adverse Change in the financial condition, results of operations, business or prospects of
the Company and the Company’s Subsidiaries taken as a whole, or (c) has, or in the Company’s
reasonable judgment could give rise to, a Company Material Adverse Effect.

4.7 Reasonable Best Efforts. Subject to the terms and conditions of this Agreement,
the Company and the Investors will use their respective reasonable best efforts to take, or cause
to be taken, all appropriate actions, to do, or cause to be done, and assist and cooperate with the
other parties in doing, all things necessary, proper or advisable to consummate, in the most
expeditious manner practicable, the transactions contemplated by this Agreement, including causing
the satisfaction and fulfillment of all the conditions set forth in Article 5. Without
limiting the foregoing, the Company shall use its reasonable best efforts, in order to cause the
condition set forth in Section 5.2(h) to be fulfilled at the Closing, to cause the
conversion of the Series G Preferred Stock to take place at the Closing or as promptly as
practicable after the Closing, and if the conversion will not occur until after the Closing, to
obtain from all the holders of the Series G Preferred Stock written assurances at or before the
Closing that on the Closing Date, effective immediately after (but subject to) the completion of
the sales of Common Stock contemplated by this Agreement and the other Investor Agreements, the
Company will have the right to cause all the shares of Series G Preferred Stock to be converted
into Common Stock.

4.8 Election of Independent Chairman; Board Representative.

(a) At or before the Closing, the Company’s Board of Directors will elect as Chairman of the
Board a person of national reputation within the banking community who (i) is independent of the
Company, the Investors and the Other Investors; (ii) has “banking or related financial management
expertise” within the meaning of 12 U.S.C. Section 1831m(g)(1)(C)(i) and 12 C.F.R. Part 363,
Appendix A, Section 32; (iii) has served, within the last three years, as the Chief Executive
Officer, President, Chief Financial Officer, Chief Risk Officer, Chief Credit Officer or
non-executive director of an insured depository institution or insured depository institution
holding company of comparable or greater size as FirstBank, and (iv) has significant experience
working with United States bank regulatory agencies. Subject to the requirements set forth in
Section 5.2(b), if the Company, despite exercising good faith best efforts, is not able to
find by the Closing Date a person with the qualifications described in the preceding sentence who
is willing to serve as Chairman of the Board, the Company will use its good faith best efforts to
identify such a person and cause that person to become Chairman of the Board as promptly as
practicable after the Closing.

(b) The Company shall cause the Board Representative to be elected or appointed, subject to
satisfaction of all legal and governance requirements regarding service as a director of the
Company and to the approval of the Company’s Corporate Governance and Nominating Committee (the
“Nominating Committee”) (such approval not to be unreasonably withheld or delayed), to the Board
of Directors on the Closing Date, and thereafter, as long as the Investors own in the aggregate at
least 25% of the number of shares of Acquired Common Stock acquired by the Investors on the
Closing Date (the “Qualifying Ownership Interest ”), the Company will include the Board
Representative among the Company’s and its directors’ nominees for election to the Board of
Directors at all of the Company’s applicable annual meetings, subject to satisfaction of all legal
and governance requirements regarding service as a director of the Company and to the approval of
the Nominating Committee (such approval not to be unreasonably withheld or delayed). If the
Nominating Committee determines that the Board Representative is not qualified to serve on the
Board of Directors of the Company, the Investors will have the right to designate a different
Board Representative. If the Investors no longer have a Qualifying Ownership Interest, the
Investors shall have no further rights under this Section 4.8 and, at the written request
of the Board of Directors, shall use all reasonable best efforts to cause their Board
Representative to resign from the Board of Directors as promptly as possible thereafter. The
Board of Directors shall cause the Board Representative to be appointed to two committees of the
Board as requested by the Board Representative, so long as the Board Representative qualifies to
serve on such committees under the applicable rules of the NYSE (or such other market as is the
principal market for the Common Stock), the SEC and the Company’s corporate governance guidelines
and the charters of such committees.

(c) The Company shall use its reasonable best efforts to cause the Board Representative to be
elected as a director of the Company by the stockholders of the Company and the Company shall
solicit proxies for the Board Representative to the same extent as it does for any of its other
nominees to the Board of Directors.

(d) Subject to Section 4.8(b), upon the death, resignation, retirement,
disqualification or removal from office of the Board Representative, the Investors shall, in
accordance with Section 4.8(g), have the right to designate the replacement for the Board
Representative, which replacement shall satisfy all legal and governance requirements regarding
service as a director of the Company. The Board of Directors of the Company shall take all action
required to fill the vacancy resulting from the death, resignation, retirement, disqualification
or removal of the Board Representative with the designated replacement, subject to satisfaction of
all legal and governance requirements regarding service as a director of the Company and to the
approval of the Nominating Committee (such approval not to be unreasonably withheld or delayed).
If the Nominating Committee determines that the designated replacement Board Representative is not
qualified to serve on the Board of Directors of the Company, the Investors will have the right to
designate a different replacement Board Representative. After a person becomes a replacement Board
Representative, the provisions of this Section 4.8 will apply to that replacement Board
Representative to the same extent they apply to predecessor Board Representatives.

(e) The Company hereby agrees that, from and after the Closing Date, for so long as the
Investors own the Qualifying Ownership Interest, the Company shall, subject to applicable law,
invite a person designated by the Investors and reasonably acceptable to the Board of Directors
(the “Observer”) to attend meetings of the Board of Directors (including any meetings of
committees thereof which the Board Representative is a member) in a nonvoting observer capacity.
If the Investors no longer own the Qualifying Interest, the Investors shall have no further rights
under this Section 4.8(e).

(f) The Board Representative shall be entitled to the same compensation and same
indemnification in connection with his or her role as a director as the other members of the Board
of Directors, and the Board Representative shall be entitled to reimbursement for documented,
reasonable out-of-pocket expenses incurred in attending meetings of the Board of Directors or any
committee thereof, to the same extent as the other members of the Board of Directors. The Company
shall notify the Board Representative and the Observer of all regular meetings and special
meetings of the Board of Directors and of all regular and special meetings of any committee of the
Board of Directors of which the Board Representative is a member. The Company shall provide the
Board Representative and Observer with copies of all notices, minutes, consents and other material
that it provides to all other members of the Board of Directors concurrently as such materials are
provided to the other members

(g) For purposes of this Agreement, “Board Representative” means Thomas M. Hagerty or such
successor as the holders of a majority of the shares of Common Stock held by the Investors shall
designate.

(h) The Company agrees that a majority of the members of the Board of Directors shall be
independent of the Company, the Investors and the Other Investors.

4.9 Access; Confidentiality.

(a) From the date of this Agreement, until the date when the shares of Common Stock owned by
the Investors represent less than the Qualifying Ownership Interest, the Company shall ensure that
upon reasonable notice, but no more than once per quarter, the Company and its subsidiaries shall
use reasonable efforts to afford to the Investors and their representatives (including officers
and employees of the Investors, and counsel, accountants and other professionals retained by the
Investors) such access during normal business hours to its books, records (including Tax returns
and appropriate work papers of independent auditors under normal professional courtesy),
properties and personnel and to such other information as the Investors may reasonably request.

(b) Except as otherwise provided in Section 12.2, each party to this Agreement shall
hold, and shall cause its respective subsidiaries and their directors, officers, employees,
agents, consultants and advisors to hold, in strict confidence, unless disclosure to a
Governmental Entity is necessary or appropriate in connection with any necessary regulatory
approval or unless compelled to disclose by judicial or administrative process or, in the written
opinion of its counsel, by other requirement of law or the applicable requirements of any
Governmental Entity, all nonpublic records, books, contracts, instruments, computer data and other
data and information (collectively “Information”) (concerning the other party hereto furnished to
it by such other party or its representatives pursuant to this Agreement (except to the extent
that such information can be shown to have been (1) previously known by such party on a
nonconfidential basis, (2) in the public domain through no fault of such party or (3) later
lawfully acquired from other sources by the party to which it was furnished), and neither party
hereto shall release or disclose such Information to any other person, except its auditors,
attorneys, financial advisors, other consultants and advisors and, to the extent permitted above,
to bank regulatory authorities.

(c) If, through the exercise of its rights under this Section 4.9 or otherwise, an Investor
obtains material non-public information about the Company, that Investor will comply with all
applicable provisions of law relating to trading on the basis of material non-public information,
including SEC Rule 10b5-1.

4.10 Conduct of the Business. Prior to the earlier of the Closing Date and the
termination of this Agreement pursuant to Article 9, the Company shall, and, shall cause each of
the Company Subsidiaries to: (a) use commercially reasonable efforts to carry on its business in
the ordinary course of business and use reasonable best efforts to maintain and preserve its and
its subsidiaries’ business (including its organization, assets, properties, goodwill and insurance
coverage) and preserve business relationships with customers, strategic partners, suppliers,
distributors and others having business dealings with it; provided, that nothing in this clause (a)
shall limit or require any actions that the Board of Directors may, in good faith, determine to be
inconsistent with, or reasonably likely to be necessary to enable the Company and the Company
Subsidiaries to be able to comply with, their duties or the Company’s obligations under applicable
law or imposed by any Governmental Entity and (b) consult with the Investors prior to taking any
material actions outside of the ordinary course of business. Without limiting the foregoing,
during the period from the date hereof until the Closing Date, the Company shall and shall cause
the Company Subsidiaries to, not take any of the following actions: (i) grant or provide any
severance or termination payments or benefits to any director, officer or employee of the Company
or any of its subsidiaries, other than as required by any Company Benefit Plans; (ii) increase the
compensation, bonus or pension, welfare, severance or other benefits of, pay any bonus to, or make
any new equity awards to any director, officer or employee of the Company or any of its
subsidiaries, other than (x) as required by any Company Benefit Plans or (y) increases in employee
salaries, or bonus awards, made in the ordinary course consistent with past practice, that do not
in aggregate exceed 5% of current aggregate employee salaries; (iii) establish, adopt, amend or
terminate any Company Benefit Plan or amend the terms of any outstanding equity-based awards,
except that the Company expects to inform employees that it intends to adopt new equity incentive
plans, or amend existing equity incentive plans, in each case, after the Closing Date, so that the
Company will be able to make equity based awards to employees with regard to up to 4% of the shares
of Common Stock that will be outstanding after the Closing and the conversion of the Series G
Preferred Stock into Common Stock; (iv) take any action to accelerate the vesting or payment, or
fund or in any other way secure the payment, of compensation or benefits under any Company Benefit
Plan, to the extent not already provided in any such Company Benefit Plan; (v) change any actuarial
or other assumptions used to calculate funding obligations with respect to any Company Benefit Plan
or to change the manner in which contributions to such plans are made or the basis on which such
contributions are determined, except as may be required by GAAP; or (vi) forgive any loans to
directors, officers or employees of the Company or any of its subsidiaries.

ARTICLE 5

CONDITIONS PRECEDENT TO TRANSACTION

5.1 Conditions to the Company’s Obligations. The obligations of the Company to
complete the transactions that are the subject of this Agreement are subject to satisfaction of the
following conditions (any or all of which may be waived by the Company):

(a) (i) The representations and warranties of the Investors contained in
Section 3.2(a) and Section 3.2(b) will be true and correct in all material respects
as of the Closing Date with the same effect as though made on such date (except that any
representation and warranty that relates to a specified date or a specified time period need only
to have been true and correct with regard to the specified date or time period) and (ii) all other
representations and warranties of the Investors contained in this Agreement will be true and
correct as of the Closing Date (without giving effect to any “material” or “materiality”
qualifications contained in such representations and warranties) with the same effect as though
made on such date (except that any representation and warranty that relates to a specified date or
a specified time period need only to have been true and correct with regard to the specified date
or time period), except, in the case of this clause (ii) only, to the extent the failure of
any such representations or warranties to be true and correct would not, individually or in the
aggregate, prevent or materially delay the ability of the Investors to perform their obligations
under this Agreement and to consummate the transactions contemplated hereby.

(b) The Investors will have fulfilled in all material respects all their obligations under
this Agreement required to have been fulfilled on or before the Closing Date.

(c) No provision of any applicable law or regulation shall exist and no order, decree,
injunction or judgment will have been entered by any Governmental Entity and be in force that
invalidates this Agreement or restrains the Company from completing the transactions that are the
subject of this Agreement and no actions or proceedings will be pending against the Company or any
of the Company Subsidiaries that, if decided against the Company or any of the Company
Subsidiaries, would materially affect the operations of the Company and the Company Subsidiaries
taken as a whole or would reasonably be expected to require the Company or any of the Company
Subsidiaries to pay damages in order to complete the transaction in an amount that would have a
Company Material Adverse Effect.

(d) The Company’s stockholders will have given the approval of the issuances of Common Stock
contemplated by the Investor Agreements that are required by NYSE listed company Rule 312.03, or
the NYSE will have informed the Company that it is not required to obtain that stockholder approval
(whether because the NYSE requirement has been satisfied by prior stockholder approvals, or because
of an exception, a waiver or otherwise).

(e) All approvals of the Federal Reserve Board, the FDIC, the OCFI and all other Governmental
Entities, including those with authority to regulate banking or insurance, that are required to be
obtained before the sales of Common Stock contemplated by the Investor Agreements can be completed
will have been obtained.

(f) The shares of Common Stock that will be issued under Investor Agreements will have been
authorized for listing on the NYSE.

(g) All the shares of Series G Preferred Stock will have been converted into the number of
shares of Common Stock determined in accordance with the Certificate of Designations relating to
the Series G Preferred Stock as in effect on the Date of this Agreement, or all the holders of
Series G Stock will have given written assurances that on the Closing Date, effective immediately
after (but subject to) the completion of the sales of Common Stock contemplated by this Agreement
and the other Investor Agreements, the Company will have the right to cause all the shares of
Series G Preferred Stock to be converted into Common Stock.

(h) The Company shall have received one or more certificates from the Investors, dated as of
the Closing Date, signed, as applicable, by an officer of each Investor, certifying that the
conditions set forth in Section 5.1(a) and 5.1(b) have been fulfilled.

5.2 Conditions to the Investor’s Obligations. The obligations of the Investors to
complete the transactions that are the subject of this Agreement are subject to satisfaction of the
following conditions (any or all of which may be waived by the Investors, and any or all of which
will be deemed waived by the Investors under the circumstances described in Section 5.3):

(a) (i) The representations and warranties of the Company contained in Section 3.1(h) will be
true and correct in all respects as of the Closing Date with the same effect as though made on such
date (except for such inaccuracies as are de minimis relative to Section 3.1(h) taken as a whole);
(ii) the representations and warranties of the Company contained in Section 3.1(a) (with
respect to the Company and its Significant Subsidiaries) and Section 3.1(c) will be true and
correct in all material respects as of the Closing Date with the same effect as though made on such
date (except that any representation and warranty that relates to a specified date or a specified
time period need only to have been true and correct with regard to the specified date or time
period); and (iii) all other representations and warranties of the Company contained in this
Agreement will be true and correct as of the Closing Date (without giving effect to any “material”
or “materiality” qualifications contained in such representations and warranties) with the same
effect as though made on such date (except that any representation and warranty that relates to a
specified date or a specified time period need only to have been true and correct with regard to
the specified date or time period), except, in the case of this clause (iii) only, to the
extent the failure of any such representations or warranties to be true and correct would not,
individually or in the aggregate, have, or reasonably be expected to have, a Company Material
Adverse Effect.

(b) The Company will have fulfilled in all material respects all its obligations under this
Agreement (including, for the avoidance of doubt, the obligations required under the first sentence
of Section 4.8(a)) required to have been fulfilled on or before the Closing Date.

(c) No provision of any applicable law or regulation shall exist and no order, decree,
injunction or judgment will have been entered by any Governmental Entity and be in force that
invalidates this Agreement or restrains any of the Investors from completing the transactions that
are the subject of this Agreement and no actions or proceedings will be pending against any of the
Investors or the Company or any of the Company Subsidiaries that, if decided against any of the
Investors or the Company or any of the Company Subsidiaries, could require an Investor to pay
damages that would be material to such Investor, would impose a Materially Burdensome Regulatory
Condition or could reasonably be expected to have a Company Material Adverse Effect.

(d) Between the date of this Agreement and the Closing Date, there will not have been a
Material Adverse Change in the financial condition, results of operations, business or prospects of
the Company and the Company Subsidiaries taken as a whole and nothing will have occurred that has
had or is likely to have a Company Material Adverse Effect.

(e) The Company’s stockholders will have given the approval of the issuance of Common Stock
contemplated by the Investor Agreements that are required by NYSE listed company Rule 312.03, or
the NYSE will have informed the Company that it is not required to obtain that stockholder approval
(whether because the NYSE requirement has been satisfied by prior stockholder approvals, or because
of an exception, a waiver or otherwise).

(f) The shares of Common Stock that will be issued under Investor Agreements will have been
authorized for listing on the NYSE.

(g) The Company will receive gross proceeds on or before the Closing Date from sales of Common
Stock under Investor Agreements (including this Agreement) totaling at least $500 million and not
more than (i) $550 million, minus (ii) the purchase price of the shares expected to be issuable on
exercise of the rights expected to be issued in the Rights Offering.

(h) All the shares of Series G Preferred Stock will have been converted into an aggregate of
not more than the number of shares of Common Stock calculated as provided in the Certificate of
Designations relating to the Series G Preferred Stock as in effect on the date of this Agreement
and all dividends and other amounts accrued or owning but unpaid in respect of the Series G
Preferred Stock shall have been paid in cash in full, or all the holders of Series G Stock will
have given written assurances that on the Closing Date, effective immediately after (but subject
to) the completion of the sales of Common Stock contemplated by this Agreement and the other
Investor Agreements, the Company will have the right to cause all the shares of Series G Preferred
Stock to be converted into Common Stock and the Company shall have delivered notice to the holders
of the Series G Preferred Stock of such conversion and done all things necessary to cause such
conversion to occur and to pay all dividends and other amounts accrued or owning but unpaid in
respect of the Series G Preferred Stock, in each case, immediately after (but subject to) the
completion of the sales of Common Stock contemplated by this Agreement and the other Investor
Agreements.

(i) The Investors will have received confirmation from the Federal Reserve Board, satisfactory
to the Investors in their reasonable judgment, to the effect that none of the Investors or any of
their affiliates (which for purposes of this paragraph shall include all “affiliates” as defined in
the Bank Holding Company Act or Regulation Y of the Federal Reserve) shall be deemed to “control”
the Company or any Company Subsidiary after the Closing Date for purposes of the Bank Holding
Company Act or Regulation Y of the Federal Reserve.

(j) All approvals of the Federal Reserve Board, the FDIC, the OCFI and all other Governmental
Entities, including those with authority to regulate banking or insurance, that are required to be
obtained before the sales of Common Stock contemplated by the Investor Agreements can be completed
will have been obtained and no such approval shall impose or contain any Materially Burdensome
Regulatory Condition.

(k) The Company shall not have received any notification from any of the FDIC, the Federal
Reserve Board and the OCFI to the effect that the capital of the Company or of FirstBank is
insufficient to meet any applicable minimum capital requirement imposed by statute, regulation or
Governmental Entity, including any requirements as to the capitalization of FirstBank contained in
or arising out of the FDIC Consent Order and the OCFI Order or as to the capitalization of the
Company contained in or arising out of the Federal Reserve Agreement, and any capital plan approved
in connection therewith and in effect. and the Company or FirstBank, as the case may be, or to the
effect that the Company will not be permitted to make acquisitions and to engage in all aspects of
its business and its currently proposed businesses without material restrictions, including the
imposition of a Materially Burdensome Regulatory Condition.

(l) The private letter ruling dated May 6, 2011, received by FirstBank from the Puerto Rico
Department of the Treasury, a true and correct copy of which has been provided to the Investors
(the “Ruling”), to the effect that the issuance of Common Stock to the Investors and the Other
Investors as contemplated by the Investor Agreements will not reduce or limit the extent to which
FirstBank can apply losses incurred in 2010 or prior years to reduce income taxes FirstBank would
be required to pay to the Commonwealth of Puerto Rico in 2011 or any subsequent year or years,
shall continue to be in full force and effect and not amended or modified in any respect.

(m) In the event FirstBank’s Puerto Rico income tax returns have been filed prior to the
Closing Date, the net operating loss carryforward of FirstBank as of December 31, 2010 as a result
of losses that are reflected on such income tax returns (at least some of which are or will be
subject to audit) will be at least $550,000,000.

(n) FirstBank shall have at least $3,475,000,000 in core deposits (including, money market,
demand, checking, savings and transactional accounts and excluding secured governmental deposits
and certificates of deposits) and at least $1,825,000,000  in certificates of deposits,
excluding governmental and brokered deposits.

(o) On the Closing Date, taking into account the transactions contemplated by the Investor
Agreements and assuming the full conversion of the Series G Preferred Stock, the Company’s Tier 1
leverage ratio shall be no lower than 10.75%.

(p) The consummation of the transactions contemplated by the Investor Agreements and the
conversion of the Series G Preferred Stock will not cause the Company or any Company Subsidiary to
be required by GAAP to establish a new cost basis for its assets through the application of push
down accounting or otherwise.

(q) The Company shall not be in default under repurchase agreements (so-called repos) or
agreements for borrowed money under which the Company has payment obligations totaling more than
$25 million.

(r) The Investors shall have received the legal opinion(s), substantially in the forms
attached hereto as Exhibit B and Exhibit C, respectively, of K&L Gates LLP and
Martinez Odell & Calabria, P.S., counsel to the Company.

(s) The Investors shall have received (A) a certificate from the Company, dated as of the
Closing Date, signed by an officer of the Company, certifying that the conditions set forth in
Section 5.1(a) and 5.1(b) have been fulfilled and (B)  the items required to be
delivered pursuant to the last sentence of Section 2.2.

5.3 Waiver of Conditions to Investor’s Obligations. If investors that have signed
Investor Agreements obligating them to purchase in total 75% of all the shares of Common Stock that
investors have agreed to purchase under all the Investor Agreements that are in effect on the
Closing Date (including this Agreement) waive any of the conditions in Section 5.2 of this
Agreement other than Section 5.2(m) and comparable provisions of their Investor Agreements, the
Investors will be deemed to have waived that condition, or those conditions, even if the Investor
does not itself waive that condition or those conditions. The condition in Section 5.2(m)
may only be waived by an Investor as to itself, and failure of the condition in that subsection
with regard to an Investor will only affect the obligations of that Investor.

ARTICLE 6

ADDITIONAL AGREEMENTS

6.1 Company Obligation Regarding Adequate Public Information. Until such time as the
Investors no longer own any Registrable Securities, the Company will:

(a) File in a timely manner all reports it is required to file under Section 13 of the
Exchange Act, except that failure to file a report on Form 8-K will not be a breach of this
Agreement.

(b) Do all things, in addition to filing required reports under Section 13 of the Exchange
Act, that are necessary so that adequate public information, as defined in Rule 144(c) under the
Securities Act, is available at all times.

(c) Upon request, furnish to the Investor a written statement as to the Company’s compliance
with the reporting conditions of Rule 144 under the Securities Act, and a copy of the most recent
annual or quarterly report of the Company (which may be a Report on Form 10-K or 10-Q); and such
other reports and documents as the Investor may reasonably request in order to meet the
requirements of any rule that would allow the Investors to sell Registrable Securities without
registration under the Securities Act.

6.2 Efforts to Maintain Listing. From the Closing Date until such time as no
Investor any longer owns any Registrable Securities, the Company will use its reasonable best
efforts to cause the Common Stock to be listed on either the New York Stock Exchange or the Nasdaq
Global Market (or a successor to one of those exchanges).

6.3 Additional Regulatory Matters

(a) The Company shall not take any action (including, any redemption, repurchase or
recapitalization of Common Stock, of securities or rights, options, or warrants to purchase Common
Stock, or securities of any type whatsoever that are, or may become, convertible into or
exchangeable into or exercisable for Common Stock) that, based on the advice of counsel, could
cause any Investor or any of its affiliates to be deemed to become, or “control”, a “bank holding
company” with respect to the Company and its affiliates within the meaning of the Bank Holding
Company Act, including the rules and regulations promulgated thereunder (or any successor
provision).

(b) Neither the Company nor the Investors shall take or permit to be taken any action that
would cause any subsidiary of the Company to become a “commonly controlled insured depository
institution” (as that term is defined for purposes of 12 U.S.C. §1815(e), as may be amended or
supplemented from time to time, or any successor provision) with respect to any institution that
is not a direct or indirect subsidiary of the Company.

(c) The Company shall not take, or permit to be taken, any action that would reasonably be
expected to cause any Investor to be subject to or bound by the FDIC’s Policy Statement on
Qualifications for Failed Bank Acquisitions, as it may be amended or supplemented from time to
time, except with the prior written consent of such Investor.

(d) In the event that any party to this Agreement breaches its obligations under this
Section 6.3 or believes that it is reasonably likely to breach such obligations, it shall
immediately notify the other parties and shall cooperate in good faith with such other parties to
modify ownership or other arrangements or take any other action, in each case, as is necessary to
cure or avoid such breach.

(e) The Company shall, and shall cause FirstBank to, take all necessary and appropriate
actions within their commercially reasonable control to:

(i) ensure the continuing application of the Ruling;

(ii) (A) supplement the ruling request submitted to the Puerto Rico Treasury Department
(the “PRTD”) on January 14, 2011 to include a request that the PRTD rule that (x) the
requirements of Puerto Rico Treasury Article 1124(b)(2)-2 were met to allow FirstBank to use
its net operating losses to offset First Leasing & Rental Corporation’s income and (y) the
transactions contemplated by this Agreement do not cause a “change of identity” or a change
in the trade or business of FirstBank (within the meaning of Puerto Rico Treasury Article
1124(b)(2)-2(a)(3)) and (B) confirm with the Puerto Rico Treasury Department by filing for a
ruling request (as may be necessary) that, with respect to the net operating losses of
FirstBank, the Company will continue to meet the requirements of Puerto Rico Treasury
Article 1124(b)(2)-2(a)(3) during the net operating losses carryover period; and

(iii) with respect to the mortgage tax credits granted by the Puerto Rico Treasury
Department that are set to expire June 30, 2011, either (x) timely transfer such credits to
one or more subsidiaries for timely application of such credits against such subsidiaries’
2010 Commonwealth of Puerto Rico Tax liability, (y) timely apply for a refund for such
credits from the Puerto Rico Treasury Department, or (z) timely sell such credits to a third
party in an arm’s-length transaction.

6.4 Percentage Maintenance Rights

(a) Sale of New Securities. After the Closing, for so long as the Investors own
Securities representing the Qualifying Ownership Interest (before giving effect to any issuances
triggering provisions of this Section 6.4), at any time that the Company makes any public
or nonpublic offering (including the Rights Offering) or sale of any equity (including Common
Stock, preferred stock or restricted stock), or any securities, options or debt that is
convertible or exchangeable into equity or that includes an equity component (such as, an “equity”
kicker) (including any hybrid security) (any such security, a “New Security”) (other than
(1) pursuant to the granting or exercise of employee stock options or other stock incentives
pursuant to the Company’s stock incentive plans approved by the Board of Directors (so long as the
authorized awards under the Company’s stock incentive plans represent less than 10% of the
outstanding shares of capital stock) or the issuance of stock pursuant to the Company’s employee
stock purchase plan approved by the Board of Directors or similar plan where stock is being issued
or offered to a trust, other entity or otherwise, for the benefit of any employees, officers or
directors of the Company, in each case, in the ordinary course of providing incentive
compensation, (2) issuances of capital stock as full or partial consideration for a merger,
acquisition, joint venture, strategic alliance, license agreement or other similar non-financing
transaction, (3) issuances of shares of Common Stock in exchange for shares of the Company’s
Series A through E Non-Cumulative Preferred Stock, or (4) issuances of shares of Common Stock upon
the conversion of the Series G Preferred Stock in accordance with the terms applicable thereto as
of the date hereof), the Investors shall be afforded the opportunity to acquire from the Company
for the same price (net of any underwriting discounts or sales commissions) and on the same terms
(except that, to the extent permitted by law and the Articles of Incorporation and By-Laws of the
Company, the Investors may elect to receive such securities in nonvoting form, convertible into
voting securities in a widely dispersed offering) as such securities are proposed to be offered to
others, up to the amount of New Securities in the aggregate required to enable it to maintain its
percentage Common Stock-equivalent interest in the Company immediately prior to any such issuance
of New Securities. The amount of New Securities that the Investors shall be entitled to purchase
in the aggregate shall be determined by multiplying (x) the total number or principal amount of
such offered New Securities by (y) a fraction, the numerator of which is the number of shares of
Common Stock held by the Investors as of such date, and the denominator of which is the number of
            shares of Common Stock then outstanding plus the number of shares of Common Stock represented by
any then-existing warrant or any other convertible securities then outstanding (if any) on an
as-exercised or as-converted basis on such date (after giving effect to any applicable adjustment
thereunder).

(b) Notice. In the event the Company proposes to offer or sell New Securities that
are subject to the Investors’ rights under Section 6.4(a), it shall give the Investors
written notice of its intention, describing the price (or range of prices), anticipated amount of
securities, timing and other terms upon which the Company proposes to offer the same (including,
in the case of a registered public offering and to the extent possible, a copy of the prospectus
included in the registration statement filed with respect to such offering), no later than five
(5) Business Days, as the case may be, after the initial filing of a registration statement with
the SEC with respect to an underwritten public offering, after the signing of an agreement with
the initial purchasers with respect to a Rule 144A offering or after the Company makes a firm
commitment to pursue any other offering. The Investors shall have ten (10) Business Days from the
date of receipt of such a notice to notify the Company in writing that they intend to exercise
their rights provided in this Section 6.4 and as to the amount of New Securities the
Investors desire to purchase, up to the maximum amount calculated pursuant to
Section 6.4(a). Such notice shall constitute a binding agreement by the Investors to
purchase the amount of New Securities so specified at the price and on the other terms set forth
in the Company’s notice to it. The failure of the Investors to respond within such ten (10)
Business Day period shall be deemed to be a waiver of the Investors’ rights under this
Section 6.4 only with respect to the offering described in the applicable notice.

(c) Purchase Mechanism. If the Investors exercise their rights provided in this
Section 6.4, the closing of the purchase of the New Securities with respect to which such
rights have been exercised shall take place on a date specified by the Company that will be not
less than ten nor more than thirty calendar days after the giving of notice of such exercise,
which period of time shall be extended for a maximum of twenty days in order to comply with
applicable laws and regulations (including receipt of any applicable regulatory or stockholder
approvals). Each of the Company and the Investors agree to use their commercially reasonable
efforts to secure any regulatory or stockholder approvals or other consents, and to comply with
any law or regulation necessary in connection with the offer, sale and purchase of, such New
Securities.

(d) Failure of Purchase. In the event the Investors fail to exercise their rights
provided in this Section 6.4 within the ten-day period described in Section 6.4(b)
or, if so exercised, the Investors are unable to consummate such purchase within the time period
specified in Section 6.4(c) above because of their failure to obtain any required
regulatory or stockholder consent or approval, the Company shall thereafter be entitled during the
period of ninety days following the conclusion of the applicable period to sell or enter into an
agreement (pursuant to which the sale of the New Securities covered thereby shall be consummated,
if at all, within thirty days from the date of such agreement) to sell the New Securities not
elected to be purchased pursuant to this Section 6.4 or which the Investors are unable to
purchase because of such failure to obtain any such consent or approval, at a price and upon other
terms that, taken in the aggregate, are not more favorable to the purchasers of such securities
than were specified in the Company’s notice to the Investors. Notwithstanding the foregoing, if
such sale is subject to the receipt of any regulatory or stockholder approval or consent or the
expiration of any waiting period, the time period during which such sale may be consummated shall
be extended until the expiration of five (5) Business Days after all such approvals or consents
have been obtained or waiting periods expired, but in no event shall such extension period exceed
ninety days from the date of the applicable agreement with respect to such sale. In the event the
Company has not sold the New Securities or entered into an agreement to sell the New Securities
within such ninety-day period (or sold and issued New Securities in accordance with the foregoing
within thirty days from the date of said agreement (as such period may be extended in the manner
described above for a period not to exceed ninety days from the date of such agreement)), the
Company shall not thereafter offer, issue or sell such New Securities without first offering such
securities to the Investors in the manner provided above.

(e) Non-Cash Consideration. In the case of the offering of securities for a
consideration in whole or in part other than cash, including securities acquired in exchange
therefor (other than securities by their terms so exchangeable), the per share purchase price to
be paid by the investors shall be cash equal to the per share fair value of the non-cash
consideration as determined by the Board of Directors (treating warrants as being exercised and
convertible securities as being converted and including any payment required on exercise of the
warrants or conversion of the convertible securities); provided, however, that
such fair value as determined by the Board of Directors shall not exceed the aggregate per share
market price of the securities being offered (treating warrants as being exercised and convertible
securities as being converted and including any payment required on exercise of the warrants or
conversion of the convertible securities) as of the date the Board of Directors authorizes the
offering of such securities.

(f) Cooperation. The Company and the Investors shall cooperate in good faith to
facilitate the exercise of the Investors’ rights under this Section 6.4, including securing any
required approvals or consents.

6.5 Participation in Other Offerings.

(a) Except as provided in Section 6.5(b) or 6.5(c), in the event this
Agreement is terminated pursuant to Section 9.1, other than a termination by the Company
under Section 9.1(b) if the Closing Date shall not have occurred by December 31, 2011
because one or more Investors has breached its representations, warranties or obligations under
this Agreement and such breach has resulted in the failure of a condition set forth in Section
5.1 to be fulfilled, each of the Investors shall have the right, for a period of one year
after the date of such termination, to participate and purchase securities in any offering of
securities by the Company on terms no less favorable to such Investor(s) than to any other
participants in such offering, including with respect to price and the type and rights of such
securities purchased and offered, in an amount to be determined by such Investors in their sole
discretion up to the lesser of (x) 24.9% of all the Common Stock that will be outstanding after
the offering and after any substantially simultaneous conversion of the Series G Preferred Stock
into Common Stock or (y) the maximum amount that will not result in such Investor or any of its
affiliates being in control of the Company or of FirstBank for purposes of the Bank Holding
Company Act or the Federal Reserve Board’s Regulation Y, or otherwise being subject to regulation
as a bank holding company under that Act.

(b) The provisions of Section 6.5(a) will not apply to (i) any transaction or series
of transactions that will result in a person or group of persons acquiring 100% of the common
stock of the Company or to any merger of the Company, or (ii) any offering of securities of the
Company as part of a merger, share exchange or other transaction in which either the Company
becomes part of, or majority owned by, another entity that results in such entity or any of its
affiliates being in control of the Company or of FirstBank for purposes of the Bank Holding
Company Act or the Federal Reserve Board’s Regulation Y, or otherwise being subject to regulation
as a bank holding company under that Act or the Company acquires at least a majority of the
outstanding equity of another entity.

(c) The provisions of Section 6.5(a) will not apply to any offering of securities to
investors if (i) the offering is fully subscribed by investors other than the Investors, (ii) the
investors who have proposed to purchase a majority of the securities the Company is offering
inform the Company in writing that if the Company issues securities to the Investors in accordance
with Section 6.5(a) the other investors will withdraw their willingness to purchase the
securities the Company is offering and (iii) the Company pays the Investors a total of
$12.5 million, minus any sum paid pursuant to Section 9.3 allocated among them in
proportion to the respective numbers of shares of Acquired Common Stock each of them has agreed in
this Agreement to purchase.

(d) If the Investors are entitled under Section 6.5(a) to participate in an offering
of securities by the Company, not later than the earliest time that any of the securities are
issued to purchasers in the offering, the Company will notify the Investors of the offering,
including the title and principal terms of the securities being offered, the price for which the
securities are being offered, and the maximum amount of the securities that the Investors are
entitled under Section 6.5(a) to purchase. The respective Investors will have 30 days from
the date they are sent that notice to notify the Company that they wish to purchase at least some
of the securities they are entitled to purchase and, if an Investor wishes to purchase less than
all the securities it is entitled to purchase, the amount of securities the Investor wishes to
purchase. An Investor will not have the right to purchase securities under Section 6.5(a)
unless it notifies the Company within the 30 day period that it wishes to purchase the securities.
A notice to the Company that an Investor wishes to purchase securities will be a binding
agreement by the Investor to purchase the securities specified in the notice.

(e) If an Investor exercise its purchase right provided in this Section 6.5, the
closing of the purchase of the New Securities with respect to which such right has been exercised
shall take place on the later of (i) a date specified by the Company that will be not less than
ten nor more than thirty calendar days after the giving of notice of such exercise, or (ii) the
earliest date on which securities are issued to any purchasers in the offering, which period of
time shall be extended for a maximum of twenty days in order to comply with applicable laws and
regulations (including receipt of any applicable regulatory or stockholder approvals). Each of
the Company and the Investors agree to use their commercially reasonable efforts to secure any
regulatory or stockholder approvals or other consents, and to comply with any law or regulation
necessary in connection with the offer, sale and purchase of, the securities.

(f) If the Investors fail to purchase the full amount of securities that they are entitled to
purchase under Section 6.5(a), the Company may, within 90 days after the end of the 30 day
period described in Section 6.5(d), sell to other persons the securities the Investors did
not purchase for a sale price not less than the price at which the securities were offered to the
Investors.

(g) The Company may issue securities that are the subject of an offering to purchasers other
than the Investors before the time when Investors must decide whether to participate in the
offering and before the Investors who elect to participate in the offering purchase securities
that are the subject of the offering.

ARTICLE 7

SALE RESTRICTIONS

7.1 Restrictions on Sales of Acquired Common Stock. No Investor will sell or
otherwise transfer any of the Acquired Common Stock, except as follows:

(a) An Investor may at any time transfer Acquired Common Stock to an entity that is an
affiliate of the Investor, as the term “affiliate” is defined in the Securities Act, or to a
general or limited partner of the Investor, but only if prior to the transfer, the affiliate or the
general or limited partner delivers to the Company a written agreement to be bound by this
Section 7.1 to the same extent as the Investor.

(b) An Investor may sell Acquired Common Stock in transactions that are registered under the
Securities Act.

(c) An Investor may sell Acquired Common Stock in transactions that are not subject to the
registration requirements of the Securities Act by reason of Rule 144 under the Securities Act.

(d) An Investor may sell Acquired Common Stock to one or more purchasers, each of which is a
qualified institutional buyer, as that term is defined in Rule 144A under the Securities Act, in
transactions that satisfy all the conditions in Rule 144A(d), but only if prior to each sale, the
purchaser delivers to the Company an agreement to be bound by this Section 7.1 to the same extent
as the Investor.

(e) An Investor may sell Acquired Common Stock in transactions that constitute “offshore
transactions,” as that term is defined in Rule 902 under the Securities Act.

(f) An Investor may sell or transfer Acquired Common Stock as part of a merger of the Investor
with another entity or in connection with a sale of all or substantially all of the Investor’s
assets to the person to whom the Investor transfers the Acquired Common Stock, but only if prior to
the merger or sale, the entity that will survive the merger or the purchaser of all or
substantially all of the Investor’s assets delivers to the Company an agreement to be bound by this
Section 7.1 to the same extent as the Investor.

ARTICLE 8

	 	 	 	 	 
	SECURITIES ACT REGISTRATION
	 	8.1	 	 	Obligation to Register Acquired Common Stock..

	 	 	 	 	 

(a) Not later than 90 days after the Closing Date, the Company will file with the SEC a
shelf registration statement (the “Shelf Registration Statement”) under SEC Rule 415 relating to
sales of Registrable Securities by the Investors and other holders of Registrable Securities. If
the Shelf Registration Statement can be filed as an automatic shelf registration statement, the
Company will file it as an automatic shelf registration statement. If the Shelf Registration
Statement cannot be filed as an automatic shelf registration statement, the Company will file it on
Form S-3, or if the Shelf Registration Statement cannot be filed on Form S-3, the Company will file
it on Form S-1 or such other form as is applicable. The Company may, instead of filing a separate
registration statement relating to the Registrable Securities, register the Registrable Securities
by filing a prospectus supplement to an existing automatic shelf registration statement or by
otherwise designating an existing shelf registration statement to cover the Registrable Securities.
The Company will use its reasonable best efforts to cause the Shelf Registration Statement to
become effective as promptly as practicable (or, if it is an automatic shelf registration
statement, to cause it to be effective when it is filed) and to keep the Shelf Registration
Statement continuously effective and available for resales of Registrable Securities until such
time as there are no remaining Registrable Securities (including by refiling the Shelf Registration
Statement, or filing a new Shelf Registration Statement, if the initial Shelf Registration
Statement expires).

(b) The term “Registrable Securities” means shares of Common Stock that are issued under
Investor Agreements (including this Agreement), except that shares of Common Stock will cease to be
Registrable Securities when (i) they are sold pursuant to an effective registration statement under
the Securities Act, (ii) they may be sold pursuant to Rule 144 without limitation on volume or
manner of sale, (iii) they cease to be outstanding or (iv) they have been sold in a private
transaction in which the transferor’s rights under this Section 8.1 are not assigned to the
Investor.

(c) If any Investors notify the Company that they intend to distribute Registrable Securities
by means of an underwritten offering, and that the aggregate public offering price of the shares
that will be the subject of the underwritten offering is estimated to be at least $25,000,000, the
Company will take all reasonable steps to facilitate that distribution, including the actions
described in Section 8.1(d). However, the Company will not be required to file or
supplement a registration statement (i) with respect to any Registrable Securities that cannot be
sold under a registration statement as a result of the transfer restrictions set forth in
Article 8; (ii) with respect to securities that are not Registrable Securities; or (iii) if
after receiving a request for registration of an underwritten distribution of Registrable
Securities from the Investor, the Company notifies the Investor and any other holders of
Registrable Securities who joined in the request that in the good faith judgment of the Company’s
Board of Directors, it would be materially detrimental to the Company or its stockholders for a
registration to be effected at the particular time, in which event the Company may defer filing a
registration statement, a post-effective amendment or a prospectus supplement relating to the
underwritten distribution of Registrable Securities for up to 90 days after receipt of the request
for registration; provided, that the Company may not exercise the right to defer filing a
registration statement, a post-effective amendment or a prospectus supplement relating to an
underwritten distribution more than twice in any 12-month period or for an aggregate of more than
180 days in any 12-month period.

(d) If during any period when the Shelf Registration Statement is not effective or available,
the Company proposes to register any of its securities, other than a registration pursuant to
Section 8.1(a) or a Special Registration, and the registration form to be filed may be used
for the registration or qualification for distribution of Registrable Securities, the Company shall
give prompt written notice to the Investors of its intention to effect such a registration (but in
no event less than ten days prior to the anticipated filing date) and shall include in such
registration all Registrable Securities with respect to which the Company has received written
requests for inclusion therein within ten Business Days after the date of the Company’s notice (a
“Piggyback Registration”). Any such person that has made such a written request may withdraw its
Registrable Securities from such Piggyback Registration by giving written notice to the Company and
the managing underwriter, if any, on or before the fifth Business Day prior to the planned
effective date of such Piggyback Registration. The Company may terminate or withdraw any
registration under this Section 8.1(d) prior to the effectiveness of such registration,
whether or not the Investors or any other Holders have elected to include Registrable Securities in
such registration. If (x) the Company grants “piggyback” registration rights to one or more third
parties to include their securities in an underwritten offering under a Shelf Registration
Statement under Section 8.1(a) or (y) a Piggyback Registration under this
Section 8.1(d) that relates to an underwritten primary offering on behalf of the Company,
and in either case the managing underwriters advise the Company that in their reasonable opinion
the number of securities requested to be included in such offering exceeds the number which can be
sold without adversely affecting the marketability of such offering (including an adverse effect on
the per share offering price), the Company shall include in such registration or prospectus only
such number of securities that in the reasonable opinion of such underwriters can be sold without
adversely affecting the marketability of the offering (including an adverse effect on the per share
offering price), which securities shall be so included in the following order of priority:
(i) first, in the case of a Piggyback Registration under Section 8.1(d), the securities the
Company proposes to sell, (ii) second, Registrable Securities of the Investors who have requested
registration of Registrable Securities pursuant to Sections 8.1(a) or 8.1(d) of
this Agreement, pro rata on the basis of the aggregate number of such securities or shares subject
to such request and (ii) third, any other securities of the Company that have been requested to be
so included, subject to the terms of this Agreement.

(e) The Company will bear all expenses of preparing and filing the Shelf Registration
Statement and all other expenses of fulfilling its obligations under this Article 8.
However, the Company will not pay any commissions, underwriting discounts or other expenses related
to an Investor’s sale of Common Stock, and the Investor will be responsible for paying all those
expenses.

(f) Whenever the Company is required to effect the registration of any Registrable Securities,
or facilitate the distribution of Registrable Securities in an underwritten offering, the Company
will, as expeditiously as reasonably practicable:

(i) Prepare and file with the SEC a registration statement, or a post-effective
amendment or prospectus supplement with regard to an already effective registration
statement, relating to the offering and sale of the Registrable Securities and keep that
registration statement effective or that prospectus supplement current until the Registrable
Securities to which it relates no longer are Registrable Securities or the underwritten
distribution has been completed or abandoned.

(ii) Prepare and file with the SEC such amendments and supplements to the applicable
registration statement and the prospectus or prospectus supplement relating to the
underwritten distribution of Registrable Securities as may be necessary to comply with the
Securities Act with respect to the distribution of the Registrable Securities to which the
registration statement or the prospectus supplement relates.

(iii) Furnish to each holder of the Registrable Securities to which the registration
statement or prospectus supplement relates and to the underwriters of any underwritten
offering of those Registrable Securities at least one copy of the registration statement
(including exhibits) and each amendment to it, and as many copies of the prospectus included
in that registration statement and any amendments or supplements to it, as each holder or
underwriter may reasonably request, and any other documents that they may reasonably request
in order to facilitate the disposition of Registrable Securities they own or are
distributing.

(iv) Use its reasonable best efforts to register and qualify the Registrable Securities
that are the subject of the registration statement or prospectus supplement under the
securities or Blue Sky laws of such, if any, jurisdictions as may reasonably be requested by
any holder or managing underwriter, and to keep that registration or qualification in effect
for as long as required by applicable law, and take any other reasonable action that may be
necessary or appropriate to enable the holders to dispose of the Registrable Securities that
are the subject of the registration or qualification, provided that the Company will not be
required to qualify to do business or to file a general consent to service of process in any
jurisdiction.

(v) At any time when holders of Registrable Securities are required to deliver
prospectuses in connection with sales of Registrable Securities, notify each holder of
Registrable Securities of the happening of any event as a result of which the applicable
prospectus includes an untrue statement of a material fact or omits to state a material fact
required to be stated therein or necessary to make the statements therein not misleading in
light of the circumstances then existing.

(g) The Company will give written notice to the Investors:

(i) When any registration statement filed pursuant to this Section 8.1 or any
amendment to such a registration statement is filed with the SEC and when any such
registration statement or any post-effective amendment to such a registration statement
becomes effective;

(ii) Of any request by the SEC for an amendment or supplement to any registration
statement filed pursuant to this Section 8.1 that relates to Registrable Securities
owned by one or more Investors or the prospectus included in any such registration
statement;

(iii) Of the issuance by the SEC of a stop order suspending the effectiveness of any
registration statement filed pursuant to this Section 8.1 that relates to
Registrable Securities owned by one or more Investors or the initiation by the SEC of a
proceeding for that purpose;

(iv) Of the receipt by the Company or its legal counsel of any notification with
respect to the suspension of the qualification of the Common Stock for sale in any
jurisdiction in which Registrable Securities owned by Investors are registered or qualified
or the initiation of any proceeding for that purpose;

(v)  Of the happening of any event that requires the Company to make changes in any
effective registration statement that relates to Registrable Securities owned by one or more
Investors or the prospectus included in any such registration statement or a supplement to
it in order to make the statements therein not misleading (which notice will be accompanied
by an instruction to suspend the use of the prospectus or prospectus supplement until the
requisite changes have been made); and

(vi) If at any time the representations and warranties of the Company contained in any
underwriting agreement relating to an underwritten distribution that includes Registrable
Securities owned by one or more Investors cease to be true and correct in all material
respects.

(h) The Company will use its reasonable best efforts to prevent the issuance, or obtain the
withdrawal, as promptly as practicable, of any order suspending the effectiveness of any
registration statement relating to Registrable Securities owned by Investors.

(i) If anything occurs that causes a registration statement, a prospectus or a prospectus
supplement relating to a sale of Registrable Securities to contain an untrue statement of a
material fact or omit to state any material fact necessary to make the statements therein, in light
of the circumstances under which they were made, not misleading, the Company will promptly prepare
a post-effective amendment to the registration statement or a supplement to the prospectus or
prospectus supplement so that the registration statement, prospectus or prospectus supplement no
longer will contain an untrue statement of a material fact or omit to state any material fact
necessary to make the statements therein, in light of the circumstances under which they were made,
not misleading . If the Company notifies Investors to suspend the use of a prospectus or
prospectus supplement until required changes have been made, each Investor will (and will cause any
underwriter of a distribution of Registrable Securities owned by the Investor to) suspend use of
that prospectus or prospectus supplement and use its reasonable best efforts to obtain the return
of any copies of the prospectus or prospectus supplement that the Investor (or the underwriters)
have given to prospective purchasers of Registrable Securities.

(j) The Company will use reasonable best efforts to procure the cooperation of the Company’s
transfer agent in settling any transfer of Registrable Securities in a transaction that is
registered under the Securities Act as contemplated by this Section 8.1.

(k) If Investors and other holders of Registrable Securities notify the Company that they
intend to distribute Registrable Securities by means of an underwritten offering, and that the
aggregate public offering price of the underwritten offering is estimated to be at least
$25,000,000, the Company will enter into an underwriting agreement in customary form, and take all
other actions that are reasonably requested by the managing underwriter, if any, to facilitate the
underwritten disposition of the Registrable Securities, including (i) making members of management
and executives of the Company available to participate in a “road show” and similar events,
(ii) making representations and warranties to the selling stockholders and the underwriters that
are customarily made by issuers in connection with underwritten public offerings by selling
stockholders, (iii) using its reasonable best efforts to obtain and furnish to the underwriters
opinions of counsel to the Company regarding the matters customarily covered in opinions given in
connection with underwritten public offerings by selling stockholders, (iv) using its reasonable
best efforts to obtain and furnish to the underwriters “comfort letters” from the firm of
independent registered public accountants that audits the Company’s financial statements (and, if
necessary, any other independent registered public accountants that audited any financial
statements included in the registration statement) and (v) delivering to the underwriters any other
documents or certificates that the managing underwriter reasonably requests.

8.2 Obligations of the Investors Regarding Registration. 

(a) No Investor will use any free writing prospectus (as defined in Rule 405 under the
Securities Act) in connection with a sale of Registrable Securities without the prior written
consent of the Company.

(b) Each Investor will, and will cause any underwriters of an underwritten offering of
Registrable Securities owned by the Investor to, furnish to the Company all information regarding
themselves, the Registrable Securities that the Investor and any other selling stockholders hold,
and the intended method of disposition of those Registrable Securities as the Company may
reasonably request for inclusion in a registration statement, prospectus or prospectus supplement
required by this Article 8. The Company will not describe the Investor as an “underwriter”
in any registration statement, prospectus or prospectus supplement without the prior written
consent of the Investor, provided that if the staff of the SEC requests that the Investor be
described as an “underwriter,” and the Investor does not consent to being described as an
underwriter, the Investor will not be eligible to include Registrable Securities it or its
affiliates own in the applicable registration statement.

8.3 Indemnification Regarding Disclosures.

(a) The Company agrees to indemnify each Investor and each Investor’s officers, directors,
employees, agents, representatives and affiliates, and each person, if any, that controls the
Investor within the meaning of the Securities Act (each, an “Indemnitee”), against any and all
losses, liabilities and expenses (including reasonable fees and expenses of attorneys and other
professionals) arising out of or based upon any untrue statement or alleged untrue statement of
material fact contained in any registration statement, prospectus or prospectus supplement that
includes Registrable Securities owned by the Investor, or any amendments or supplements to any of
them or any documents incorporated by reference in any of them or contained in any free writing
prospectus prepared by the Company or authorized by it in writing for use by the Investor; or any
omission or alleged omission to state in any such document a material fact required to be stated
therein or necessary to make the statements therein, in light of the circumstances under which they
were made, not misleading; provided, that the Company will not be liable to any Indemnitee to the
extent that any loss, liability or expense results from (i) a claim relating to information
provided by the Investor or an underwriter of an offering that includes Registrable Securities
owned by the Investor for use in connection with the applicable registration statement, prospectus
or prospectus supplement, or (ii) an offer or sale effected “by means of” (as defined in Rule 159A
under the Securities Act) a “free writing prospectus” that was not prepared or authorized in
writing by the Company.

(b) If the indemnification provided for in Section 8.3(a) is not available to an
Indemnitee with respect to any loss, liability or expenses referred to in that Section or is not
sufficient to hold the Indemnitee harmless as contemplated in that Section, then the Company, in
lieu of indemnifying that Indemnitee, will contribute to the amount paid or payable by that
Indemnitee in such proportion as is appropriate to reflect the relative fault of the Indemnitee, on
the one hand, and the Company, on the other hand, in connection with the statements or omissions
which resulted in the loss, liability or expenses as well as any other relevant equitable
considerations. The relative fault of the Company, on the one hand, and of the Indemnitee, on the
other hand, will be determined by reference to, among other factors, whether the untrue statement
of a material fact or omission to state a material fact relates to information supplied by the
Company or by the Indemnitee and the parties’ relative intent, knowledge, access to information and
opportunity to correct or prevent the statement or omission. The Company and the Investors agree
that it would not be just and equitable if contribution under this Section 8.3 were
determined by pro rata allocation or by any other method of allocation that does not take account
of those equitable considerations. No Indemnitee that is guilty of fraudulent misrepresentation
(as that term is used with regard to Section 11(f) of the Securities Act) will be entitled to
contribution from the Company if the Company was not guilty of fraudulent misrepresentation.

8.4 Assignment of Registration Rights. The rights of an Investor to registration of
Registrable Securities under this Article 8 may be assigned by the Investor to any
transferee of Registrable Securities if (i) the Investor transfers to that transferee Registrable
Securities with a market value at the time of transfer of at least $5,000,000, (ii) the transfer is
permitted under the terms of this Agreement and (iii) the Investor or the transferee has furnished
to the Company written notice of the name and address of the transferee and the number of
Registrable Securities that were, or are being, transferred to the transferee, and the transferee
agrees in writing to be bound by this Article 8, including Section 8.3.

8.5 Lock Up Agreements. If the Company proposes to sell securities in an underwritten
public offering or an offering under SEC Rule 144A with an expected public offering price of at
least $25,000,000, and a managing underwriter or lead initial purchaser of that offering tells the
Company that failure to suspend sales of Registrable Securities could adversely affect the amount
of securities the Company can sell or the price for which the Company can sell the securities, at
the request of the Company, each Investor will enter into an agreement with the underwriters or
initial purchasers to suspend sales of Registrable Securities for a period not exceeding 90 days.
In the event an Investor enters into such an agreement, the Company will use its reasonable best
efforts to cause each of the Other Investors which at the time own, together with its affilates, at
least as many shares of Common Stock as the Investors and their affiliates, and each of the
Company’s senior executive officers, to execute an agreement with substantially the same terms and
conditions and for the same time period to which such Investor is bound. An Investor will not be
required to enter into an agreement of that type more than twice in any twelve month period.

8.6 Holdback. With respect to any underwritten offering of Registrable Securities by
the Investors or other Holders pursuant to this Article 8, the Company agrees not to effect
(other than pursuant to such registration or pursuant to a Special Registration) any public sale or
distribution, or to file any Shelf Registration Statement (other than such registration or a
Special Registration) covering any of its equity securities, or any securities convertible into or
exchangeable or exercisable for such securities, during the period not to exceed ten days prior and
60 days following the effective date of such offering or such longer period up to 90 days as may be
requested by the managing underwriter. The Company also agrees to cause each of its directors and
senior executive officers to execute and deliver customary lockup agreements in such form and for
such time period up to 90 days as may be requested by the managing underwriter. For purposes of
this Agreement, the term “Special Registration” means the registration of (a) equity securities
and/or options or other rights in respect thereof solely registered on Form S-4 or Form S-8 (or
successor form) or (b) shares of equity securities and/or options or other rights in respect
thereof to be offered to directors, members of management, employees, consultants, customers,
lenders or vendors of the Company or Company Subsidiaries or in connection with dividend
reinvestment plans.

ARTICLE 9

TERMINATION

9.1 Right to Terminate. This Agreement may be terminated at any time prior to the
earlier of the payment by the Investors of the purchase price for the Acquired Common Stock, or the
issuance of the Acquired Common Stock to the Investors, as described in Section 2.2:

(a) By mutual consent of the Investors and the Company.

(b) By either the Investors or the Company by July 31, 2011 if, by such date, the Company has
not entered into Investor Agreements (including this Agreement) relating to sales of Common Stock
for at least $500 million (but the right to terminate this Agreement pursuant to this Section
9.1(b) will end when the Company has entered into Investor Agreements (including this Agreement)
relating to sales of Common Stock for at least $500 million).

(c) By either the Investors or the Company if the Closing Date shall not have occurred by
December 31, 2011 (the “Termination Date”); provided, however, that a party shall
not be entitled to terminate this Agreement pursuant to this Section 9.1(c) if such party
has breached any of its representations, warranties or obligations under this Agreement (including
each such party’s obligations under Section 4.7 or 4.8, as applicable) and such
breach was a material reason for the failure of a condition set forth in Section 5.1 or
5.2, as applicable, to be fulfilled.

(d) By either the Investors or the Company if either of them is informed by a Governmental
Agency that an approval or other action by that Governmental Agency that is required to enable the
sale of Common Stock contemplated by this Agreement to take place will not be given or taken by
that Governmental Agency.

(e) By either the Investors or the Company if any applicable law or regulation shall be in
force or any final and non-appealable order, decree, injunction or judgment shall have been entered
by any Governmental Entity that invalidates this Agreement or prevents or restrains any of the
parties hereto from completing the transactions that are the subject of this Agreement.

(f) By either the Investors or the Company if a stockholders meeting is held as contemplated
by Section 4.1, and at that meeting, the Company’s stockholders vote on, but do not
approve, the proposal to approve the transactions that are the subject of the Investor Agreements.

(g) By the Company, at any time prior to the Closing, if (i) any Investor is in breach of its
representations, warranties or covenants made by it in this Agreement; (ii) such breach is not
cured or capable of being cured by the earlier of the day prior to the Termination Date and thirty
days following written notice of such breach from the Company and (iii) such breach, if uncured,
would render any condition set forth in Section 5.1 incapable of being satisfied.

(h) By the Investors, at any time prior to the Closing, if (i) the Company is in breach of its
representations, warranties or covenants made by it in this Agreement; (ii) such breach is not
cured or capable of being cured by the earlier of the day prior to the Termination Date and thirty
days following written notice of such breach from the Investors and (iii) such breach, if uncured,
would render any condition set forth in Section 5.2 incapable of being satisfied.

9.2 Manner of Terminating Agreement. If at any time the Investors or the Company have
the right under Section 9.1 to terminate this Agreement, they or it can terminate this
Agreement by a notice to the other of them that they are or it is terminating this Agreement at a
time specified in the notice (which may be the time the notice is given).

9.3 Effect of Termination. If this Agreement is terminated pursuant to this
Article 9, after this Agreement is terminated, neither the Investors nor the Company will
have any further rights or obligations under this Agreement, except that (i) the provisions of
Section 6.5 will remain in effect until one year after the day on which this Agreement is
terminated, and (ii) if this Agreement is terminated under Section 9.1(f), within 10 days
after this Agreement is terminated, the Company will pay to the Investors the sum of $5 million
minus any sum paid pursuant to Section 6.5(c), which will be allocated among them in
proportion to the respective numbers of shares of Acquired Common Stock each of them has agreed in
this Agreement to purchase. Nothing contained in this Article 9 will relieve any party of
liability for any breach of this Agreement that occurs before this Agreement is terminated or for
any reimbursement obligations under the letter agreement dated May 26, 2011 between the Company and
Thomas H. Lee Partners, L.P.

ARTICLE 10

INDEMNIFICATION

10.1 Indemnification Against Loss Due to Inaccuracies in Company’s Representations and
Warranties or Company Failure to Fulfill Obligations. Subject to the limits in
Section 10.3, the Company indemnifies the Investors against, and agrees to hold the
Investors harmless from, all losses, liabilities and expenses (including, but not limited to,
reasonable fees and expenses of counsel and expenses of investigation) incurred by the Investor
directly or indirectly because (i) any matter that is the subject of a representation and warranty
contained in Section 3.1 is not as represented and warranted (without giving effect to any
“material”, “materiality”, “material adverse change” or “material adverse effect” qualification
contained in any such representation and warranty), or (ii) the Company fails to fulfill in any
respect any of its obligations under this Agreement, or under any document delivered in accordance
with this Agreement, which is required to be fulfilled after the Closing Date.

10.2 Indemnification Against Loss Due to Inaccuracies in Investor’s Representations and
Warranties or Investor Failure to Fulfill Obligations. Subject to the limits in Section 10.3,
each Investor indemnifies the Company against, and agrees to hold the Company harmless from, all
losses, liabilities and expenses (including, but not limited to, reasonable fees and expenses of
counsel and expenses of investigation) incurred by the Company directly or indirectly because (i)
any matter that is the subject of a representation and warranty contained in Section 3.2 is not as
represented and warranted (without giving effect to any “material”, “materiality”, “material
adverse change” or “material adverse effect” qualification contained in any such representation and
warranty), or (ii) the Investor fails to fulfill in any respect any of its obligations under this
Agreement, or under any document delivered in accordance with this Agreement, which is required to
be fulfilled after the Closing Date.

10.3 Limit on Liability for Breach of Warranty.

(a) Except with respect to breaches of the representations and warranties contained in
Sections 3.1(a) (Organization and Power), 3.1(c) (Authorization) and 3.1(g)
(Issuance of Acquired Common Stock), or in Section 3.1(u) (Taxes) (but only with respect to
the representations and warranties in that Section with respect to the amount and ability to apply
net operating loss carryforward of FirstBank as of December 31, 2010, which shall be the only
portion of Section 3.1(u) that is not subject to the limitations in this Section 10.3), and
in instances of knowing fraud, the Company will not be liable to any Investor under
Section 10.1, or any other provision of this Agreement, as a result of a breach of the
Company’s representations and warranties in Section 3.1, to the extent the losses,
liabilities and expenses for which the Investor would, except for this Section 10.3(a), be
entitled to indemnification under Section 10.1 are in total less than 2% or more than 15%
of the Aggregate Purchase Price the Investor has agreed in Section 1.1 to pay for the
Acquired Common Stock it is purchasing. The Company will have no obligation to reimburse the
Investor for the amount that is less than 2% or more than 15% of the Aggregate Purchase Price the
Investor has agreed in Section 1.1 to pay for the Acquired Common Stock it is purchasing.
In determining the amount of losses, no breach of a representation and warranty that results in a
loss of less than $50,000 will be included.

(b) Except in instances of knowing fraud, no Investor will be liable under
Section 10.2, or any other provision of this Agreement, as a result of a breach of such
Investor’s representations and warranties in Section 3.2, to the extent the losses,
liabilities and expenses for which the Company would, except for this Section 10.3(b), be
entitled to indemnification from the Investor under Section 10.2 are in total less than 2%
or more than 15% of the total purchase price the Investor has agreed in Section 1.1 to pay
for the Acquired Common Stock, and the Investor will have no obligation to reimburse the Company
for the amount that is less than 2% or more than 15% of the total purchase price the Investor has
agreed in Section 1.1 to pay for the Acquired Common Stock. In determining the amount of
losses, no breach of a representation and warranty that results in a loss of less than $50,000 will
be included.

10.4 Indemnification Sole Remedy. Except in instances of knowing fraud, the
indemnification in Sections 10.1 and 10.2, as the case may be, will be the sole
remedy of the Investors or the Company, as applicable, as a result of a breach of a representation
and warranty contained in Section 3.1 or 3.2, as applicable. Except as to claims
with respect to breaches of the representations and warranties in Section 3.1(u) (Taxes), any claim
for indemnification must be made in a written notification to the party from which indemnification
is sought, must describe in reasonable detail the claim and the facts on which such claim is based
and, with respect to claims for indemnification arising under Section 10.1(i) or
Section 10.2(i) must be given not later than the day that is two years after the Closing
Date. Neither the Company nor the Investors will have any liability for any breach of a
representation and warranty contained in Section 3.1 or 3.2 unless a claim is made
in accordance with this Section 10.4.

ARTICLE 11

ABSENCE OF BROKERS

11.1 Representations and Warranties Regarding Brokers and Others. The Company and the
Investors each represent and warrant to the other of them that nobody acted as a broker, a finder
or in any similar capacity in connection with the transactions that are the subject of this
Agreement, except that Sandler O’Neill & Partners, L.P. acted as financial adviser to the Company
(there may be a finder with regard to sales of Common Stock to some Other Investors, who will be
entitled to a fee from the Company equal to 1% of the purchase price paid by those Other
Investors). The Company will pay all the fees and other charges of Sandler O’Neill & Partners,
L.P. The Company indemnifies the Investors and agrees to hold each of them harmless from, and the
Investors jointly and severally indemnify the Company, against and agree to hold the Company
harmless from, all losses, liabilities and expenses (including, but not limited to, reasonable fees
and expenses of counsel and costs of investigation) incurred because of any claim by anyone for
compensation as a broker, a finder or in any similar capacity by reason of services allegedly
rendered to the indemnifying party or its subsidiaries in connection with the transactions which
are the subject of this Agreement.

11.2 Expenses. Except as specifically provided in this Agreement or in the letter
agreement dated May 26, 2011 between the Company and Thomas H. Lee Partners, L.P., each of the
Investors and the Company will pay its own expenses in connection with the transactions that are
the subject of this Agreement, including legal fees and disbursements.

ARTICLE 12

GENERAL

12.1 Announcement of Transaction. The Company will, not later than one Business Day
after Investors and Other Investors have signed Investor Agreements (including this Agreement)
relating to purchases of Common Stock for a total of at least $500 million, make a public
announcement, in a form to be provided to and approved in advance by the Investors in their
reasonable discretion, of the signing of such Investor Agreements in sufficient detail so that the
fact that Investor Agreements have been signed and knowledge of the terms of the Investor
Agreements will not constitute material non-public information. The Company will also timely make
all filings with the SEC that are required under the Exchange Act with respect to the execution of
the Investor Agreements and the issuance of Common Stock under the Investor Agreements. The
Company will not, without the consent of the Investors, mention the names of the Investors or of
their advisers in any public disclosures regarding the transactions that are the subject of the
Investor Agreements, except that nothing in this Section or elsewhere in this Agreement will
prevent the Company from disclosing the name of any Investor or its investment adviser to the
extent it is required to do so by law, by rules of the SEC or the NYSE, or by any form the Company
is required to file with a Governmental Entity, or to the extent it is asked for that information
by any Governmental Entity (including, but not limited to, the staff of the SEC, the FDIC, the
Federal Reserve or the OCFI); provided, however, that the Company will, to the
extent reasonably practicable, provide the Investors with a reasonable opportunity to review and
comment on such disclosures and filings in advance.

12.2 Entire Agreement. This Agreement, the non-disclosure agreement dated
March 25, 2011 between the Company and Thomas H. Lee Partners, L.P. and the letter agreement dated
May 26, 2011 between the Company and Thomas H. Lee Partners, L.P. contain the entire agreement
between the Company and the Investors relating to the transactions that are the subject of this
Agreement, and supersede all prior negotiations, understandings and agreements between the Company
and any of the Investors, and there are no representations, warranties, understandings or
agreements concerning the transactions that are the subject of this Agreement other than those
expressly set forth in this Agreement, the non-disclosure agreement dated March 25, 2011 between
the Company and Thomas H. Lee Partners, L.P. and the letter agreement dated May 26, 2011 between
the Company and Thomas H. Lee Partners, L.P. The Company has provided a good faith estimate of the
estimated amount of transaction expenses that will be incurred by the Company and the Company
Subsidiaries and their advisors prior to or in connection with the Closing Date.

12.3 Benefit of Agreement. This Agreement is for the benefit of, and will bind, the
parties to it, their respective successors and any permitted assigns. This Agreement is not
intended to be for the benefit of, or to give any rights to, anybody other than the parties, their
respective successors and any permitted assigns. Without limiting the generality of the foregoing,
no investor other than the Investors will have any claim against the Company or any of the
Investors under or by reason of this Agreement.

12.4 Captions. The captions of the Articles and Sections of this Agreement are for
convenience only, and do not affect the meaning or interpretation of this Agreement.

12.5 Assignments. Neither this Agreement nor any right of any party under it may be
assigned, except that (i) any Investor may assign its rights to acquire the Acquired Common Stock
to an affiliate, provided, however, that, in such event, such Investor and such
affiliate will be jointly and severally liable for any failure of the affiliate to fulfill any of
the Investor’s obligations under this Agreement and (ii) if an Investor transfers Registrable
Securities to another person under circumstances and in a manner that entitles the transferee to
registration rights as provided in Section 8.3(c), the Company will be deemed to have
entered into an agreement with the transferee giving the transferee all the rights with regard to
the transferred Registrable Securities that the Investor had immediately before the transfer.

12.6 Notices and Other Communications. Any notice or other communication under this
Agreement must be in writing and will be deemed given when it is delivered in person or sent by
facsimile or electronic mail (with proof of receipt at the facsimile number or email address to
which it is required to be sent), on the Business Day after the day on which it is delivered to a
major overnight delivery service marked for next business day delivery, or on the third Business
Day after the day on which it is mailed by first class registered or certified mail, return receipt
requested, from within the United States or Puerto Rico to the address below (or to such other
address as may be specified after the date of this Agreement by the party to which the notice or
communication is sent):

(a) If to the Investors (or any of them):

c/o Thomas H. Lee Partners, L.P.

100 Federal Street, 35th Floor

Boston, MA 02110

Attn: Thomas M. Hagerty

Facsimile: 617-227-3514

with a copy to (which copy alone shall not constitute notice):

Weil, Gotshal & Manges LLP

100 Federal Street, 34th Floor

Boston, MA 02110

Attn: Marilyn French and James Westra

Facsimile: 617-772-8333

Email: Marilyn French@weil.com

Email: James.Westra@weil.com

with a copy to (which copy alone shall not constitute notice):

Davis Polk & Wardwell LLP

450 Lexington Avenue

New York, New York 10017

Attn: John L. Douglas

Facsimile: (212) 701-5145

Email Address: john.douglas@davispolk.com

(b) If to the Company

First BanCorp

1519 Ponce de Leon Avenue

San Juan, Puerto Rico 00908

Attention: General Counsel

Facsimile No.: 787-753-8402

Email Address: lawrence.odell@firstbankpr.com

with a copy to (which copy alone shall not constitute notice):

K&L Gates LLP

599 Lexington Avenue

New York, NY 10022

Attention: David W. Bernstein

Facsimile No.: 212-536-3901

Email Address: david.bernstein@klgates.com

Any notice or communication given hereunder shall be deemed given on (a) if received on a Business
Day on or before 5:00 p.m. local time of the recipient, the date of receipt, or (b) if received on
a day other than a Business Day or on a Business Day after 5:00 p.m. local time of the recipient,
the first Business Day following the date of receipt.

12.7 Governing Law. This Agreement and all disputes arising out of or relating to
this Agreement and the subject matter hereof or the actions of the parties hereto in the
negotiation, execution, administration, performance or nonperformance, enforcement, interpretation,
termination and construction hereof and all matters based upon, arising out of or related to any of
the foregoing (whether based on contract, tort or otherwise), including all matters of
construction, validity and performance, shall be governed by and construed in accordance with the
internal laws, both procedural and substantive, of the State of New York, without regard to
conflicts of laws principles (whether of the State of New York or any other jurisdiction) that
would apply the laws of any jurisdiction other than the State of New York.

12.8 Consent to Jurisdiction. The Company and each Investor each agrees that any
action or proceeding relating to this Agreement or the transactions that are the subject of this
Agreement shall be brought in any state or Federal court sitting in the Borough of Manhattan in the
State of New York, and in no other court, and each of them (i) consents to the personal
jurisdiction of each of those courts in any such action or proceeding, (ii) agrees not to seek to
transfer any such action or proceeding to any other court, whether because of inconvenience of the
forum or for any other reason (but nothing in this Section 12.9 will prevent a party from
removing any action or proceeding from a state court sitting in the Borough of Manhattan to a
Federal court sitting in that Borough) and (iii) agrees that process in any such action or
proceeding may be served by registered mail or in any other manner permitted by the rules of the
court in which the action or proceeding is brought.

12.9 Remedies; Specific Performance. The parties acknowledge that money damages may
not be an adequate remedy if the Company or any Investor failed to perform in any material respect
any of its obligations under this Agreement, and accordingly they agree that in addition to any
other remedy to which a party may be entitled at law or in equity, each party will be entitled to
seek to obtain an order compelling specific performance of the other party’s or parties’
obligations under this Agreement, without any requirement that the party seeking specific
performance post a bond, and the parties agree that if any proceeding is brought in equity to
compel performance of any provision of this Agreement, no party will raise the defense that there
is an adequate remedy at law. No remedy will be exclusive of any other remedy to which a party may
be entitled, and the remedies available to a party will be cumulative.

12.10 Non-Recourse. All claims or causes of action (whether in contract or in tort,
in law or in equity) that may be based upon, arise out of or relate to this Agreement, or the
negotiation, execution or performance of this Agreement (including any representation or warranty
made in or in connection with this Agreement or as an inducement to enter into this Agreement), may
be made only against the entities that are expressly identified as parties hereto. No person who
is not a named party to this Agreement, including without limitation any past, present or future
director, officer, employee, incorporator, member, partner, equityholder, Affiliate, agent,
attorney or representative of any named party to this Agreement, shall have any liability (whether
in contract or in tort, in law or in equity, or based upon any theory that seeks to impose
liability of an entity party against its owners or affiliates) for any obligations or liabilities
arising under, in connection with or related to this Agreement or for any claim based on, in
respect of, or by reason of this Agreement or its negotiation or execution; and each party hereto
waives and releases all such liabilities, claims and obligations against any such person who is not
a named party to this Agreement.

12.11 Waiver of Jury Trial. EACH OF THE PARTIES TO THIS AGREEMENT IRREVOCABLY WAIVES
ALL RIGHTS TO TRIAL BY JURY IN ANY ACTION OR PROCEEDING RELATING TO THIS AGREEMENT OR THE
TRANSACTIONS CONTEMPLATED BY THIS AGREEMENT, INCLUDING ANY ACTION OR PROCEEDING BROUGHT BY WAY OF
COUNTERCLAIM. EACH OF THE PARTIES ACKNOWLEDGES THAT IT IS AWARE THAT THIS WAIVER OF RIGHTS TO JURY
TRIAL WAS A FACTOR IN EACH OTHER PARTY’S DECISION TO AGREE TO THE TERMS OF THIS AGREEMENT AND THAT
NOBODY PROMISED THAT THIS WAIVER OF THE RIGHT TO JURY TRIAL WOULD NOT BE ENFORCED.

12.12 Amendments. This Agreement may be amended by, but only by, a document in
writing signed by both the Company and all the Investors.

12.13 Interpretation. The table of contents and headings contained in this Agreement
are for reference purposes only and shall not affect in any way the meaning or interpretation of
this Agreement. Except to the extent otherwise provided or when the context otherwise requires,
references to Sections, Articles or Exhibits contained herein refer to Sections, Articles or
Exhibits of this Agreement. Whenever the words “include”, “includes”, or “including” are used in
this Agreement, they are deemed to be followed by the words “without limitation”. The words
“hereof”, “herein”, and “hereunder”, and words of similar import, when used in this Agreement,
refer to this Agreement as a whole and not to any particular provision of this Agreement. All
terms defined in this Agreement have the defined meanings when used in any certificate or other
document made or delivered pursuant hereto, unless otherwise defined therein. The definitions
contained in this Agreement are applicable to the singular as well as the plural forms of such
terms. References to a person are also to its successors and permitted assigns. The use of “or”
is not intended to be exclusive unless expressly indicated otherwise. All Exhibits annexed hereto
or referred to herein are hereby incorporated in and made a part of this Agreement as if set forth
in full herein. A reference that a statement is made “to the knowledge of the Company” means that
no officer of the Company has actual knowledge of facts that are inconsistent with that statement.

12.14 Mutual Drafting. The parties hereto are sophisticated and have been represented
by lawyers who have carefully negotiated the provisions hereof. As a consequence, the parties do
not intend that the presumptions of any laws or rules relating to the interpretation of contracts
against the drafter of any particular clause should be applied to this Agreement and therefore
waive their effects.

12.15 Severability. If any provision of this Agreement or the application of any such
provision to any person or circumstance shall be held invalid, illegal or unenforceable in any
respect by a court of competent jurisdiction, such invalidity, illegality or unenforceability shall
not affect any other provision hereof.

12.16 Counterparts. This Agreement may be executed in two or more counterparts, some
of which may be signed by fewer than all the parties or may contain facsimile copies of pages
signed by some of the parties. Each of those counterparts will be deemed to be an original copy of
this Agreement, but all of them together will constitute one and the same agreement.

(Signatures on following page)

IN WITNESS WHEREOF, the Company and the Investors have executed this Agreement,
intending to be legally bound by it, as of the day shown on the first page of this Agreement.

FIRST BANCORP

By:

Title:

1

INVESTOR:

THOMAS H. LEE (ALTERNATIVE FUND VI, L.P.

By: THL Advisors (Alternative) VI, L.P., its
general partner

By: Thomas H. Lee Advisors (Alternative) VI,
Ltd., its general partner

By:

Name: Thomas M. Hagerty

Title: Director

Name ...Thomas H. Lee (Alternative) Fund VI, L.P.

Form of entity ...Exempted limited partnership

Jurisdiction of formation ...Cayman Islands

Taxpayer Identification No. ...98-0494653

Number of shares being acquired ........................................................

Name in which securities should be registered ...............................................................

Total Purchase Price $.............................................

Shares already owned by Investor or affiliates ...0

Exhibit A

Illustrative Pro Forma Capitalization of the Company

(see attached)

2

Exhibit B

Form of Opinion of K&L Gates LLP

(see attached)

3

Exhibit C

Form of Opinion of Martinez Odell & Calabria

(see attached)

4

Schedule 3.2

No Conflict; Consents and Approvals

(see attached)

5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00190-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00190-of-00352.parquet"}]]